Vous êtes sur la page 1sur 308

1 2 3

Particulars of Information ACI ACIFORMULA ACMELAB


Trading Code
Last Trading Price 366 162.6 88.8
Change* 5.6 1.6 0.2
Opening Price 360 161.1 88.6
Adjusted Opening Price 360.4 161 88.6
Yesterday's Closing Price 360.4 161 88.6
Closing Price 364.3 161.5 88.6
Day's Range 360.00 - 366.90159.00 - 162.60 88.20 - 89.20
Day's Value (mn) 5.644 2.249 9.238
52 Weeks' Moving Range 329.90 - 638.40157.00 - 217.20 88.10 - 122.00
Day's Volume (Nos.) 15,579 14,044 104,100
Day's Trade (Nos.) 188 66 299
Market Capitalization (mn) 17,372 7,245 18,748
Authorized Capital (mn) 500 500 5000
Paid-up Capital (mn) 482 450 2,116
Face/par Value 10 10 10
Total No. of Outstanding Securities 48,202,442 45,000,000 211,601,700
Cash Dividend 115% 2017, 11535% 2017, 35% 201635% 2017, 35%
Bonus Issue (Stock Dividend) 10% 2017, 10% 50% 2011, 20% 2008-
Right Issue 1R:1(At Par) 19 - -
Year End Jun-18 Jun-18 Jun-18
Reserve & Surplus without OCI (mn) 9,591 1,996 9,709
Other Comprehensive Income (OCI) (mn) 98 - 4
Listing Year 1976 2008 2016
Market Category A A A
Electronic Share Y Y Y
Share Holding Percentage [as on Jun 30, 2017 (year ended)]
Sponsor/Director: 44.5 66.02 39.95
Govt: 0 0 0
Institute: 29.33 21.02 25.55
Foreign: 0 0 2.97
Public: 26.17 12.96 31.53
Share Holding Percentage [as on Jun 30, 2018]
Sponsor/Director: 45.48 66.02 40.12
Govt: 0 0 0
Institute: 28.63 24.2 28.94
Foreign: 0 0 2.68
Public: 25.89 9.78 28.26
Share Holding Percentage [as on Jul 31, 2018]
Sponsor/Director: 45.48 66.02 40.12
Govt: 0 0 0
Institute: 28.59 24.8 29.63
Foreign: 0 0 1.45
Public: 25.93 9.18 28.8
EPS Information (Audited Financials)
Last year(Basic) 24.31 5.85 6.61
Last year (Re-stated) -- -
Last year (Diluted) -- -
NAV Information (Last year) 241.29 54.35 80.13

Last Dividend Declaration Date:


4 5 6 7 8 9 10

ACTIVEFINE ADVENT AFCAGRO AMBEEPHA BEACONPHAR BXPHARMA BXSYNTH

37.8 37 39.8 620 18.3 86.5 7.8


1.1 1 1 -14.7 0.2 -0.4 0
36.9 37 38.8 629.5 18.1 86.9 8.3
36.7 36 38.8 634.7 18.1 86.9 7.8
36.7 36 38.8 634.7 18.1 86.9 7.8
37.6 36 39.3 615.7 18.3 86.4 8
36.20 - 38.00 35.50 - 36.90 38.80 - 40.00 610.00 - 643.9018.00 - 18.40 86.30 - 87.90 7.80 - 8.30
70.042 2 7.077 7.934 2.424 20.826 0.225
28.20 - 50.70 31.70 - 55.00 33.70 - 61.50 360.00 - 875.0017.50 - 23.30 84.50 - 113.50 7.50 - 16.30
1,862,497 53,947 179,488 12,608 133,875 240,765 27,602
733 139 130 386 87 513 34
7,338 2,435 3,534 1,523 4,181 35,243 676
3000 1,000 1000 25 3000 9100 2000
1,999 686 911 24 2,310 4,056 867
10 10 10 10 10 10 10
199,947,150 68,600,000 91,080,000 2,400,000 231,000,000 405,556,445 86,712,359
5% 2016 - - 30% 2017, 26% 5% 2017, 5% 2012.5% 2017, 15 -
25% 2017, 30% - 20% 2017, 20% 20% 2013 5% 2011 5% 2016, 5% 2010% 2012, 15%
- - - n/a - Merger with Bx n/a
Jun-18 43,281 Jun-18 Jun-18 Jun-18 Jun-18 Jun-18
922 119 415 37 680 15,745 929
3 - (0) - 1 3 -
2010 2,018 2014 1986 2010 1986 1993
A N A A B A Z
Y Y Y Y Y Y Y

12.02 31.44 30.29 75.26 0 13.18 35.67


0 0 0 0 0 0 0
31.42 15.6 38.45 4.41 0 24.01 13.4
3.06 0 0 0 0 41.45 0.02
53.5 52.96 31.26 20.33 0 21.36 50.91

12.04 31.44 30.29 75.26 http://www.bea 13.19 35.67


0 0 0 0 0 0 0
33.7 21.01 33.38 7.17 0 29.3 12.64
3.11 0 0 0 0 40.79 0.02
51.15 47.55 36.33 17.57 0 16.72 51.67

12.04 31.44 30.29 75.26 0 13.19 35.67


0 0 0 0 0 0 0
32.4 19.96 35.3 4.87 0 29.7 12.68
3.11 0 0 0 0 40.05 0.02
52.45 48.6 34.41 19.87 0 17.06 51.63
3.46 3.49 3.02 0 5.49 -2.62
- - - 0- -
- - - 0- -
24.45 0 17.47 25.24 0 61.82 20.71
11 12 13 14 15 16 17

CENTRALPHL FARCHEM GHCL GLAXOSMITH IBNSINA IMAMBUTTON JMISMDL

15.7 18.2 41.7 1131.9 288 22.3 202.5


0.4 0.4 0.7 54.2 4.7 0.7 5.7
15.3 17.9 41 1084 285 22.8 200
15.3 17.8 41 1077.7 283.3 21.6 196.8
15.3 17.8 41 1077.7 283.3 21.6 196.8
15.6 18 41.7 1129.6 287.2 22.1 202.5
15.20 - 15.70 17.70 - 18.20 41.00 - 43.00 1,083.00 - 1,134283.80 - 292.8022.00 - 22.80 196.30 - 203.90
3.773 18.334 9.01 0.274 15.744 0.038 3.138
14.00 - 29.30 15.40 - 25.90 36.10 - 56.90 1,005.00 - 1,700232.50 - 345.0018.20 - 47.30 167.10 - 239.80
243,399 1,020,404 213,895 243 54,453 1,714 15,565
178 650 286 42 468 5 142
1,746 3,208 2,952 12,982 8,047 166 2,165
3000 3000 1000 200 500 100 1000
1,141 1,802 720 120 284 77 110
10 10 10 10 10 10 10
114,096,042 180,242,498 72,000,000 12,046,449 28,403,298 7,700,000 11,000,000
- 5% 2016 10% 2017, 15% 550% 2017, 50025% 2017, 37.5 - 30% 2017, 35%
10% 2017, 10% 10% 2017, 20% - n/a 10% 2017, 15% 10%B 2010 -
- - - n/a n/a n/a -
Jun-18 Jun-18 Jun-18 Dec-18 Jun-18 Jun-18 Jun-18
600 635 2,072 2,510 791 (29) 634
- - - - 30 - -
2013 2014 2013 1976 1989 1996 2013
A A A A A Z A
Y Y Y Y Y Y Y

30 30.24 69.03 81.98 43.83 31.53 49.31


0 0 0 0 0 0 0
13.36 27.2 16.13 15.98 18.83 15.38 9.46
0 0 0 0.74 0 0 12.73
56.64 42.56 14.84 1.3 37.34 53.09 28.5

25.89 30.24 69.03 81.98 44.47 31.53 49.31


0 0 0 0 0 0 0
13.21 29.95 20.46 15.93 17.38 9.01 10.46
0 0 0 0.91 0 0 11.82
60.9 39.81 10.51 1.18 38.15 59.46 28.41

25.89 30.24 69.03 81.98 44.47 31.53 49.31


0 0 0 0 0 0 0
12.62 30.12 15.33 15.86 15.77 9.01 14.85
0 0 0 0.92 0 0 11.82
61.49 39.64 15.64 1.24 39.76 59.46 24.02
1.05 1.79 1.08 55.56 9.06 -0.38 6.78
- - - - - - -
- - - - - - -
16.78 15.24 53.82 218.35 42.79 6.22 67.64
18 19 20 21 22 23 24

KEYACOSMET KOHINOOR LIBRAINFU MARICO ORIONINFU ORIONPHARM PHARMAID

8.2 401.2 681.2 1130 52.6 38.8 546.3


0.2 3.9 10.5 -6.7 0.9 0.3 2.9
8 402 670.7 1140 52.2 38.5 543.4
8 397.3 670.7 1136.7 51.7 38.5 543.4
8 397.3 670.7 1136.7 51.7 38.5 543.4
8 401.9 672 1130.5 52.2 38.7 545
8.00 - 8.20 396.10 - 402.00650.00 - 692.601,130.00 - 1,14051.70 - 52.80 38.40 - 39.20 542.50 - 553.90
19.531 0.661 3.64 0.687 1.777 3.965 13.929
7.90 - 16.30 365.00 - 482.00480.00 - 1,334. 1,010.00 - 1,29345.10 - 68.90 37.70 - 51.80 262.30 - 707.00
2,424,689 1,652 5,387 608 33,946 102,832 25,452
600 49 308 18 131 81 656
8,017 5,568 839 35,806 1,053 9,009 1,695
15000 500 100 400 1000 5000 50
10,021 140 13 315 204 2,340 31
10 10 10 10 10 10 10
### 14,015,625 1,251,600 31,500,000 20,359,760 234,000,000 3,120,000
- 15% 2017, 10% 30% 2017, 25% 600% 2018, 50014% 2017, 14% 15% 2017, 15% 35% 2017, 30%
20% 2017, 18% 15% 2017, 20% n/a - - 20% 2012 500% 2010
1R:1 2012, 1R:5n/a n/a - 1:1R 1996 - n/a
Jun-18 Jun-18 Jun-18 Mar-18 Jun-18 Jun-18 Jun-18
2,808 414 1,963 923 45 6,315 123
- - - 2 7 (70) -
2001 1988 1994 2009 1994 2013 1987
A A A A A A A
Y Y Y Y Y Y Y

62.77 48.72 0 90 40.61 31.98 28.44


0 0 0 0 0 0 0
5.75 16.18 0 2.81 21.64 40.95 5.85
0 0 0 6.4 0.26 4.04 0
31.48 35.1 0 0.79 37.49 23.03 65.71

46.27 48.72 0 90 40.61 31.98 24.22


0 0 0 0 0 0 0
8.59 14.38 0 2.74 26.02 46.83 3.38
0 0 0 6.53 0.14 4 0
45.14 36.9 0 0.73 33.23 17.19 72.4

46.27 48.72 0 90 40.61 31.98 24.22


0 0 0 0 0 0 0
8.4 14.38 0 2.74 25.79 47.11 3.38
0 0 0 6.53 0.14 4 0
45.33 36.9 0 0.73 33.46 16.91 72.4
2.01 12.04 0 52.15 1.53 3.4 9.48
- - 0- - - -
- - 0- - - -
15.37 45.46 0 47.38 12.57 70.95 49.53
25 26 27 28 29 30

RECKITTBEN RENATA SALVOCHEM SQURPHARMA WATACHEM

1688 1230 26.2 275.9 310


-12 -0.9 0.8 -0.5 -0.7
1734 1230 25.2 276.3 307
1700 1230.9 25.4 276.4 310.7
1700 1230.9 25.4 276.4 310.7
1696 1229.3 26.1 276.2 310.2
1,672.00 - 1,734.00 1,220.00 - 1,23225.20 - 26.50 275.30 - 280.90306.10 - 313.00
1.314 2.494 7.105 55.548 5.951
1,470.20 - 2,280.00 1,055.00 - 1,32018.30 - 30.90 263.00 - 335.00160.70 - 352.90
772 2,031 275,280 200,506 19,249
28 109 147 1079 231
8,033 86,201 1,573 203,815 2,834
250 1000 1500 10000 150
47 700 619 7,374 91
10 10 10 10 10
4,725,000 70,031,022 61,926,471 737,391,090 9,121,613
790% 2017, 775% 201130% 2017, 85%- 35% 2017, 40% 10% 2017,10% 2016
1B:4 96, 1B:2 88, 1B: 15% 2017, 15% 5% 2017, 5% 207.5% 2017, 10%5% 2017, 10% 2016, 25% 2014, 30% 2013, 20% 2012
n/a n/a - - -
Dec-18 Jun-18 Jun-18 Jun-18 Jun-18
263 12,224 83 39,289 551
(7) 18 - 330 -
1987 1979 2011 1995 1992
A A B A A
Y Y Y Y Y

82.96 51.16 22.14 Y 39.42


3.77 0 0 0 0
5.95 17.18 14.03 0 33.09
2.7 21.78 0 0 0
4.62 9.88 63.83 0 27.49

82.96 51.16 22.14 36.34 36.41


3.77 0 0 0 0
5.94 16.63 9.32 9.82 37.5
2.7 22.03 0 19.75 0
4.62 10.18 68.54 34.09 26.09

82.96 51.16 22.14 34.43 36.41


3.77 0 0 0 0
5.95 18.07 11.16 10.12 37.5
2.95 22.29 0 19.85 0
4.37 8.48 66.7 35.6 26.09
80.63 43.98 0.79 15.51 4.13
- - - - -
- - - - -
64.28 212.54 11.91 71.47 77.65
, 30% 2013, 20% 2012
Company Name: ACI Limited

Company Information

Trading Code: ACI

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 18/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End
Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)

Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

2015-16*
2017

Financial Performance... (Continued)

Year

2014

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company


Address

Contact Phone

Fax

E-mail

Web Address
Scrip Code: 18455

366

4:00 PM

5.6

1.55%

360

360.4

360.4

364.3

360.00 - 366.90

5.644

329.90 - 638.40

15,579

188

17,372.16

500

482.02

10

48,202,442

Equity

Pharmaceuticals & Chemicals

Total Trade Graph:

For the year ended: Jun 30, 2017

115% 2017, 115% 2016

10% 2017, 10% 2016, 15% 2014, 20% 2013, 20% 2012, 20% 2011, 20% 2008, 20% 1997, 25% 1996, 100% 1994, 100% 1983.

1R:1(At Par) 1997

30-Jun
9,590.90

98.4

Unaudited / Audited

Q1

Ending on

201709

12648.12

113.62

113.62

113.62

2.59

2.59

579.1

12-Aug-18

30.5

12-Aug-18

14.97

16.47

Jan'15-Dec'15
Jan'16-Jun'16

Jan'15-Jun'16

Jan'15-Dec'15

Jan'16-Jun'16

Jan'15-Jun'16

http://www.aci-bd.com/financial.php
http://www.aci-bd.com/financial.php

1976

Sponsor/Director:

44.5

Sponsor/Director:

45.48

Sponsor/Director:

45.48
1. TK 4,277,933,521 Revaluation Reserve has been added to Reserve & Surplus. 2. Conversion of ACI 20% Convertible Zero Coupon Bonds
into 2,46,232 number of ACI ordinary shares by exercising the 5th series of convertibility option.

Short-term loan (mn)

Long-term loan (mn)

Short-term

Long-term
ACI Centre, 245 Tejgaon I/A, Dhaka - 1208

880 2 8878603, 8878611-16, 9556254

880 2 8878619, 8878626

info@aci-bd.com

http://www.aci-bd.com
Total Volume Graph:
Q2 Half Yearly Q3 9 Months Annual

Ending on 6 Months Ending on 201803 Ending on

201712 201712 201803

15685.19 28333.31 14493.34 42826.66 -

271.36 384.98 46.27 431.25 -

271.36 384.98 46.27 431.25 -

271.36 384.98 46.27 431.25 -

5.63 7.99 0.96 8.95 -

- - - - -

5.63 7.99 0.96 8.95 -

- - - - -

459.8 459.8 399.1 399.1 -

13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

30.54 30.38 30.42 30.2 30.53

- - - - -

13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

14.99 14.91 14.93 14.83 14.99

16.49 16.4 16.43 16.31 16.48

Earnings per share(EPS) EPS - Continuing Operations NAV Per Share

Basic Diluted Basic Diluted

Original Restated Original Restated Original Restated Diluted

- - - 16.68 - - 120.3 103.93 -

- - - 72.25 - - 245.3 - -
- - - 9.59 - - - - -

- - - 81.85 74.41 - 243.72 221.56 -

- - - 24.31 - - 241.29 - -

Year end Price Earnings (P/E) ratio Dividend in %* Dividend Yield in %

Earnings per share(EPS) EPS - Continuing Operations

Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 27.09 - - 100.00,15%B 2.56

- - - 7.77 - - - -

- - - 47.44 - - - -

- - - 5.56 6.12 - 115.00, 10%B 2.53

- - - 21.25 - - 115.00, 10%B 2.23

Govt: Institute: Foreign: Public:

0 29.33 0 26.17

Govt: Institute: Foreign: Public:

0 28.63 0 25.89

Govt: Institute: Foreign: Public:

0 28.59 0 25.93

Active

19675.65

5151.45

115.00, 10%B for 2017


Profit/(Loss) and
OCI
PCO* Profit for the year (mn) TCI*

573.45 - -

2878.37 2878.37 2878.37


382.17 382.17 382.17

3260.54 3260.54 6455.9

1065.16 1065.16 1163.51


Company Name: ACI Formulations Limited

Company Information

Trading Code: ACIFORMULA

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 18/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

2015-16*

2017
Financial Performance... (Continued)

Year

2014

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18480

162.6

4:00 PM

1.6

0.99%

161.1

161

161

161.5

159.00 - 162.60

2.249

157.00 - 217.20

14,044

66

7,245.00

500

450

10

45,000,000

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

35% 2017, 35% 2016

50% 2011, 20% 2008

30-Jun

1,995.70

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

664.02 1294.37 1958.39 1374.96 3333.35 -

5 96.99 102 21.37 123.37 -

5 96.99 102 21.37 123.37 -

5 96.99 101.99 21.37 123.37 -

0.11 2.16 2.27 0.47 2.74 -

- - - - - -

0.11 2.16 2.27 0.47 2.74 -

- - - - - -

200 173.6 173.6 181.9 181.9 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

43.85 43.58 43.47 43.93 44.07 44.21

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

27.38 27.21 27.15 27.44 27.52 27.61

- - - - - -

Earnings per share(EPS) EPS - Continuing Operations


NAV Per Share
Basic Basic
Diluted Diluted
Original Restated Original Restated Original

- - - 4.14 - - 40.1

Jan'15-Dec'15 - - - 5.06 - - 52.02

Jan'16-Jun'16 - - - 1.98 - - -

Jan'15-Jun'16 - - - 7.04 - - 50.5

- - - 5.85 - - 54.35
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %*
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 30.82 - - 30

Jan'15-Dec'15 - - - 37.5 - - -

Jan'16-Jun'16 - - - 78.19 - - -

Jan'15-Jun'16 - - - 22.02 - - 35

- - - 34.22 - - 35

http://www.aci-bd.com/financial.php
http://www.aci-bd.com/financial.php

2008

Sponsor/Director: Govt: Institute: Foreign: Public:

66.02 0 21.02 0 12.96

Sponsor/Director: Govt: Institute: Foreign: Public:

66.02 0 24.2 0 9.78

Sponsor/Director: Govt: Institute: Foreign: Public:

66.02 0 24.8 0 9.18

TK 1,136,392,931 Revaluation Reserve has been added Reserve & Surplus.

Active

Short-term loan (mn) 1881.36

Long-term loan (mn) 0

35.00 for 2017

Short-term

Long-term

ACI Centre, 245 Tejgaon, Industrial Area, Dhaka-1208

8802 8878603, 8878611-16, 9556254


88-02-8878619, 8878626

info@aci-bd.com,

http://www.aci-bd.com/acifl/
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Restated Diluted

- - 186.46 - -

- - 227.64 227.64 227.64

- - 89.21 89.21 89.21

- - 316.85 316.85 761.4

- - 263.14 263.14 263.14


Dividend Yield in %

2.35

2.26

1.75
Company Name: The ACME Laboratories Limited

Company Information

Trading Code: ACMELAB

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 04/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2013

2014

2015

2016

2017
Financial Performance... (Continued)

Year

2013

2014

2015

2016

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address
Address

Contact Phone

Fax

E-mail

Web Address
Scrip Code: 18491

88.8

4:00 PM

0.2

0.23%

88.6

88.6

88.6

88.6

88.20 - 89.20

9.238

88.10 - 122.00

104,100

299

18,747.91

5,000.00

2,116.02

10

211,601,700

07 Jun, 2016

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

35% 2017, 35% 2016

30-Jun

9,708.70

4
Unaudited / Audited

Q1 Q2 Half Yearly Q3

Ending on Ending on 6 Months Ending on

201709 201712 201712 201803

3572.51 3669.7 7242.21 3659.32

421.11 385.2 806.31 391.44

421.11 385.2 806.31 391.44

424.16 387.83 811.99 391.27

1.99 1.82 3.81 1.85

- - - -

1.99 1.82 3.81 1.85

- - - -

113.2 114 114 102.5

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18

11.81 11.77 11.97 12.03

- - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18

13.48 13.43 13.66 13.74

- - - -

Earnings per share(EPS)

Basic
Diluted
Original Restated

- - -

- - -

- - -

- - -

- - -
Year end Price Earnings (P/E) ratio

Earnings per share(EPS)

Using Basic EPS Using

Original Restated Diluted EPS

- - -

- - -

- - -

- - -

- - -

2016

Sponsor/Director: Govt: Institute: Foreign:

39.95 0 25.55 2.97

Sponsor/Director: Govt: Institute: Foreign:

40.12 0 28.94 2.68

Sponsor/Director: Govt: Institute: Foreign:

40.12 0 29.63 1.45


1. Data are provided as per company prospectus. 2. The NAV & EPS of last Financial Statements have been calculated considering Post-IPO Number of Shares. 3. TK
5,487,674,207 Revaluation Reserve has been added to Reserve & Surplus.

Active

Short-term loan (mn) 5304.04

Long-term loan (mn) 3025.88

35.00 for 2017

Short-term

Long-term

The ACME Laboratories Limited

ACME Group
Court de la ACME

1/4, Mirpur Road, Kallayanpur,

Dhaka - 1207, Bangladesh.

+88 02 9004194-6

+88 02 9016872

headoffice@acmeglobal.com

http://acmeglobal.com
9 Months Annual

201803 Ending on

10901.53 -

1197.75 -

1197.75 -

1203.26 -

5.66 -

- -

5.66 -

- -

102.5 -

19-Aug-18 20-Aug-18

11.74 11.74

- -

19-Aug-18 20-Aug-18

13.4 13.4

- -

EPS - Continuing Operations Profit/(Loss) and OCI


NAV Per Share
Basic
Diluted PCO* Profit for the year (mn) TCI*
Original Restated Original Restated Diluted

4.19 - - 61.15 - - 505.7 505.7 505.7

5.65 - - 66.16 - - 893.89 893.89 894.73

5.7 - 4.36 70.37 - 73.1 921.92 921.92 922.9

6.55 - - 77.34 - - 1101.27 1101.27 1101.27

6.61 - - 80.13 - - 1397.85 1397.85 1401.83


P/E) ratio

EPS - Continuing Operations


Dividend in %* Dividend Yield in %
Using Basic EPS Using

Original Restated Diluted EPS

- - - - -

- - - - -

- - - - -

17.77 - - 35 3.01

17.51 - - 35 3.03

2016

Public:

31.53

Public:

28.26

Public:

28.8
Number of Shares. 3. TK
Company Name: Active Fine Chemicals Limited

Company Information

Trading Code: ACTIVEFINE

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 14/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

2015-16*

2017
Financial Performance... (Continued)

Year

2014

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address
Address

Contact Phone

Fax

E-mail

Web Address
Scrip Code: 18483

37.8

4:00 PM

1.1

3.00%

36.9

36.7

36.7

37.6

36.20 - 38.00

70.042

28.20 - 50.70

1,862,497

733

7,338.06

3,000.00

1,999.47

10

199,947,150

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

5% 2016

25% 2017, 30% 2016, 20% 2014, 20% 2013, 25% 2012, 20% 2011, 15% 2010

30-Jun

922.4

2.6
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

545 560.37 1105.37 582.78 1688.14 -

128.41 138.35 266.76 134.74 401.5 -

128.41 138.35 266.76 134.74 401.5 -

128.41 138.35 266.76 134.74 401.5 -

0.8 0.69 1.33 0.67 2.01 -

- - - - - -

0.8 0.69 1.33 0.67 2.01 -

- - - - - -

44.8 35.2 35.2 30.6 30.6 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

13.4 13.36 13.92 14.25 13.69 14.03

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

10.38 10.35 10.78 11.04 10.61 10.87

12.96 12.92 13.47 13.79 13.25 13.57

Earnings per share(EPS) EPS - Continuing Operations

ear Basic Basic


Diluted
Original Restated Original Restated

014 - - - 4.26 -

Jan'15-Dec'15 - - - 3.7 -

Jan'16-Jun'16 - - - 1.81 -

Jan'15-Jun'16 - - - 5.51 4.24

017 - - - 3.46 -
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


ear
Using Basic EPS Using Using Basic EPS

Original Restated Diluted EPS Original Restated

014 - - - 25.31 -

Jan'15-Dec'15 - - - 15.18 -

Jan'16-Jun'16 - - - 26.49 -

Jan'15-Jun'16 - - - 8.69 11.3

017 - - - 14.64 -

2010

Sponsor/Director: Govt: Institute: Foreign: Public:

12.02 0 31.42 3.06 53.5

Sponsor/Director: Govt: Institute: Foreign: Public:

12.04 0 33.7 3.11 51.15

Sponsor/Director: Govt: Institute: Foreign: Public:

12.04 0 32.4 3.11 52.45

TK 107,546,742 Revaluation Reserve has been added to Reserve & Surplus.

Active

Short-term loan (mn) 808.87

Long-term loan (mn) 1.17

25%B for 2017

Short-term

Long-term

Navana Osman @ Link,

Holding No. 214/D,


Gulshan - Tejgaon Link Road,

Dhaka – 1208

88-02-8836830, 8836843, 8836854, 8836875

880-2-8836825

n/a

http://www.afchem.com
S - Continuing Operations Profit/(Loss) and OCI
NAV Per Share

Diluted PCO* Profit for the year (mn) TCI*


Original Restated Diluted

- 27.09 22.42 - 359.16 - -

- 26.81 - - 455.68 455.68 558.93

- - - - 222.49 222.49 209.96

- 28.52 21.94 - 678.17 678.17 768.88

- 24.45 - - 553.89 553.89 556.5


atio

S - Continuing Operations
Dividend in %* Dividend Yield in %
Using

Diluted EPS

- 6.00, 20%B 0.81

- - -

- - -

- 5.00, 30%B 1.04

- 25%B -
Company Name: Advent Pharma Limited

Company Information

Trading Code: ADVENT

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on:

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**


Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2016

2017

Financial Performance... (Continued)

Year

2016

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status


OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone

Fax

E-mail

Web Address
Scrip Code: 18492

36.8

4:00 PM

1.3

3.66%

36.5

35.5

35.5

36.3

35.50 - 36.90

1.949

31.70 - 55.00

53,947

139

2,435.30

1,000.00

686

10

68,600,000

12 Apr, 2018

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

30-Jun

119.3

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3

Ending on Ending on 6 Months Ending on

201709 201712 201712 201803

- 0 0 94.57

31.65Mismatch is due

- 15.3 to issuer's own 17.55

actual disclosure

31.65Mismatch is due

- 15.3 to issuer's own 17.55

actual disclosure

31.65Mismatch is due

- 15.3 to issuer's own 17.55

actual disclosure

0.650Mismatch is due

- 0.31 to issuer's own 0.33

actual disclosure

- - - -

0.650Mismatch is due

- 0.31 to issuer's own 0.33

actual disclosure

0.460Mismatch is due

- 0.22 to issuer's own -

actual disclosure

- - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18

28.7 28.32 27.93 28.01

- - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18

52.82 52.11 51.41 51.55


- - - -

Earnings per share(EPS)

Basic
Diluted
Original Restated

- - -

- - -

Year end Price Earnings (P/E) ratio

Earnings per share(EPS)

Using Basic EPS Using

Original Restated Diluted EPS

- - -

- - -

2018

Sponsor/Director: Govt: Institute: Foreign:

31.44 0 15.6 0

Sponsor/Director: Govt: Institute: Foreign:

31.44 0 21.01 0

Sponsor/Director: Govt: Institute: Foreign:

31.44 0 19.96 0
1.The NAV & EPS of last Financial Statements have been calculated considering Post-IPO Number of Shares. 2. Share Holding Percentage shows based on post-IPO
paid up capital of the Company as per Company's letter dated March 19, 2018.

Active

Short-term loan (mn) 10

Long-term loan (mn) 26.54

Short-term
Long-term

Green Homes,Flat # 2 B, House 10/7, Block# A,

Iqbal road, Mohammadpur, Dhaka-1207.

-9185266

-9185265

adventpharma@gmail.com

http://www.adventpharmabd.com
9 Months Annual

201803 Ending on

279.45Mismatch is due

to issuer's own -

actual disclosure

49.2Mismatch is due

to issuer's own -

actual disclosure

49.2Mismatch is due

to issuer's own -

actual disclosure

49.2Mismatch is due

to issuer's own -

actual disclosure

0.980Mismatch is due

to issuer's own -

actual disclosure

- -

0.980Mismatch is due

to issuer's own -

actual disclosure

- -

- -

19-Aug-18 20-Aug-18

27.17 27.78

- -

19-Aug-18 20-Aug-18

50 51.13
- -

EPS - Continuing Operations Profit/(Loss) and OCI


NAV Per Share
Basic
Diluted PCO* Profit for the year (mn) TCI*
Original Restated Original Restated Diluted

2.34 - - 17.07 - - 27.86 27.86 27.86

1.49 - 0.71 12.45 - 11.74 48.69 48.69 48.69

rice Earnings (P/E) ratio

EPS - Continuing Operations


Dividend in %* Dividend Yield in %
Using Basic EPS Using

Original Restated Diluted EPS

- - - - -

- - - - -

2018

Public:

52.96

Public:

47.55

Public:

48.6
Holding Percentage shows based on post-IPO
Company Name: AFC Agro Biotech Ltd.

Company Information

Trading Code: AFCAGRO

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 14/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

2015-16*

2017
Financial Performance... (Continued)

Year

2014

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on May 31, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address
Address

Contact Phone

Fax

E-mail

Web Address
Scrip Code: 18489

39.8

4:00 PM

2.58%

38.8

38.8

38.8

39.3

38.80 - 40.00

7.077

33.70 - 61.50

179,488

130

3,533.90

1,000.00

910.8

10

91,080,000

11 Feb, 2014

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

20% 2017, 20% 2016, 15% 2014, 10% 2013

30-Jun

415.1

-0.2
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

255.14 258.75 513.9 258.85 772.72 -

64.76 66.36 131.12 65.14 196.25 -

64.76 66.36 131.12 65.14 196.25 -

64.76 66.36 131.12 65.14 196.25 -

0.85 0.73 1.44 0.72 2.15 -

- - - - - -

0.85 0.73 1.44 0.72 2.15 -

- - - - - -

54.4 45 45 34.8 34.8 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

13.5 13.43 13.67 13.85 13.53 13.71

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

11.09 11.03 11.23 11.38 11.12 11.26

13.3 13.23 13.47 13.64 13.33 13.51

Earnings per share(EPS) EPS - Continuing Operations


NAV Per Share
Basic Basic
Diluted Diluted
Original Restated Original Restated Original

- - - 2.83 - - 13.41

Jan'15-Dec'15 - - - 3.36 - - 15.01

Jan'16-Jun'16 - - - 1.76 - - -

Jan'15-Jun'16 - - - 5.12 4.27 - 16.78

- - - 3.49 - - 17.47
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %*
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 17.31 - - 15%B

Jan'15-Dec'15 - - - 21.09 - - -

Jan'16-Jun'16 - - - 33.06 - - -

Jan'15-Jun'16 - - - 11.39 13.65 - 20%B

- - - 17.04 - - 20%B

2014

Sponsor/Director: Govt: Institute: Foreign: Public:

30.29 0 38.45 0 31.26

Sponsor/Director: Govt: Institute: Foreign: Public:

30.29 0 33.38 0 36.33

Sponsor/Director: Govt: Institute: Foreign: Public:

30.29 0 35.3 0 34.41

Active

Short-term loan (mn) 92.9

Long-term loan (mn) 0

20%B for 2017

Short-term

Long-term

Navana Osman @ Link,

Holding No. 214/D,


Gulshan - Tejgaon Link Road,

Dhaka – 1208

88-02-8836830, 8836843, 8836854, 8836875

880-2-8836825

afc.agro@gmail.com

http://www.afcagrobiotech.com
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Restated Diluted

- - 154.81 154.81 154.81

- - 212.31 212.31 212.16

- - 111.55 111.55 111.84

13.98 - 323.86 323.86 324

- - 264.6 264.6 264.41


Dividend Yield in %

-
Company Name: Ambee Pharmaceuticals Ltd.

Company Information

Trading Code: AMBEEPHA

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 21/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

2015-16*

2017
Financial Performance... (Continued)

Year

2014

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address
Contact Phone

Fax

E-mail

Web Address
Scrip Code: 18451

620

4:00 PM

-14.7

-2.32%

629.5

634.7

634.7

615.7

610.00 - 643.90

7.934

360.00 - 875.00

12,608

386

1,523.28

25

24

10

2,400,000

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

30% 2017, 26% 2016

20% 2013

n/a

30-Jun

36.6

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

88.03 90.32 178.35 93.81 272.16 -

1.79 1.97 3.76 2.28 6.04 -

1.79 1.97 3.76 2.28 6.04 -

1.79 1.97 3.76 2.28 6.04 -

0.75 0.82 1.57 0.95 2.52 -

- - - - - -

0.75 0.82 1.57 0.95 2.52 -

- - - - - -

415.3 387.2 387.2 378.1 378.1 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

200.21 214.61 209.2 204.2 188.9 183.24

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

222.75 238.77 232.75 227.19 210.17 203.87

- - - - - -

Earnings per share(EPS) EPS - Continuing Operations


NAV Per Share
Basic Basic
Diluted Diluted
Original Restated Original Restated Original

- - - 3.13 - - 24.21

Jan'15-Dec'15 - - - 2.71 - - 24.12

Jan'16-Jun'16 - - - 0.7 - - -

Jan'15-Jun'16 - - - 3.14 - - 24.82

- - - 3.02 - - 25.24
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %*
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 82.01 - - 28

Jan'15-Dec'15 - - - 101.59 - - -

Jan'16-Jun'16 - - - 416.01 - - -

Jan'15-Jun'16 - - - 84.93 - - 26

- - - 134.35 - - 30

1986

Sponsor/Director: Govt: Institute: Foreign: Public:

75.26 0 4.41 0 20.33

Sponsor/Director: Govt: Institute: Foreign: Public:

75.26 0 7.17 0 17.57

Sponsor/Director: Govt: Institute: Foreign: Public:

75.26 0 4.87 0 19.87

8.95 % Foreign Director including in the Share holding % of Sponsor/Director

Active

Short-term loan (mn) 188.63

Long-term loan (mn) 0

30.00 for 2017

Short-term

Long-term

184/1, Tejgaon Industrial Area

Dhaka-1208
(880-2) 8870777, 8870788, 8878534

(880-2) 8870799

info@ambeepharma.com

http://www.ambeepharma.com
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Restated Diluted

- - 7.52 - -

- - 6.51 6.51 6.51

- - 1.67 1.67 1.67

- - 8.18 8.18 8.18

- - 7.25 7.25 7.25


Dividend Yield in %

1.09

0.9

0.74
Company Name: Beacon Pharmaceuticals Limited

Company Information

Trading Code: BEACONPHAR

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 28/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS


Year

2013

2014

2015

2016

2017

Financial Performance... (Continued)

Year

2013

2014

2015

2016

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)


Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone

Fax

E-mail

Web Address
Scrip Code: 18482

18.3

4:00 PM

0.2

1.10%

18.1

18.1

18.1

18.3

18.00 - 18.40

2.424

17.50 - 23.30

133,875

87

4,181.10

3,000.00

2,310.00

10

231,000,000

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

5% 2017, 5% 2016

5% 2011

30-Jun

680.3

1
Unaudited / Audited

Q1 Q2 Half Yearly Q3

Ending on Ending on 6 Months Ending on

201709 201712 201712 201803

912.24 887.11 1799.35 879.36

48.81Mismatch is due

24.13 26.35 to issuer's own 32.61

actual disclosure

48.81Mismatch is due

24.13 26.35 to issuer's own 32.61

actual disclosure

48.44Mismatch is due

23.96 26.14 to issuer's own 31.96

actual disclosure

0.210Mismatch is due

0.1 0.11 to issuer's own 0.14

actual disclosure

- - - -

0.210Mismatch is due

0.1 0.11 to issuer's own 0.14

actual disclosure

- - - -

21.2 21.3 21.3 19.2

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18

37.71 37.5 38.57 39.43

- - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18

39.11 38.89 40 40.89

- - - -
Earnings per share(EPS)

ear Basic
Diluted
Original Restated

013 - - -

014 - - -

015 - - -

016 - - -

017 - - -

Year end Price Earnings (P/E) ratio

Earnings per share(EPS)


ear
Using Basic EPS Using

Original Restated Diluted EPS

013 - - -

014 - - -

015 - - -

016 - - -

017 - - -

http://www.beacon-pharma.com/investor.html
http://www.beacon-pharma.com/investor.html

2010

Sponsor/Director: Govt: Institute: Foreign:

30 0 17.29 0

Sponsor/Director: Govt: Institute: Foreign:

30 0 23.49 0

Sponsor/Director: Govt: Institute: Foreign:

30 0 23.37 0

Tk 298,663,002 Revaluation Surplus has been added to Reserve & Surplus.

Active

Short-term loan (mn) 919.41

Long-term loan (mn) 976.65

5.00 for 2017


Short-term

Long-term

Beacon Business Centre, 9/A, Toyenbee Circular Road, Motijheel C/A, Dhaka-1000.

-57164499

-57164501

beacon@beaconpharma.com.bd

http://www.beaconpharma.com.bd
9 Months Annual

201803 Ending on

2678.72 -

80.05Mismatch is due

to issuer's own -

actual disclosure

80.05Mismatch is due

to issuer's own -

actual disclosure

79.03Mismatch is due

to issuer's own -

actual disclosure

0.350Mismatch is due

to issuer's own -

actual disclosure

- -

0.350Mismatch is due

to issuer's own -

actual disclosure

- -

19.2 -

19-Aug-18 20-Aug-18

38.79 39.21

- -

19-Aug-18 20-Aug-18

40.22 40.67

- -
EPS - Continuing Operations Profit/(Loss) and OCI
NAV Per Share
Basic
Diluted PCO* Profit for the year (mn) TCI*
Original Restated Original Restated Diluted

0.04 - - 11.94 - - 9.13 - -

0.1 - - 12.41 - - 24.23 - -

0.17 - - 12.58 - - 38.56 38.56 38.56

0.27 - - 13 - - 61.4 61.4 95.96

0.45 - - 12.95 - - 103.73 103.73 104.71

nd Price Earnings (P/E) ratio

EPS - Continuing Operations


Dividend in %* Dividend Yield in %
Using Basic EPS Using

Original Restated Diluted EPS

352.5 352.5 - - -

148 148 - - -

86.47 - - - -

64.07 - - 5 2.89

51.44 - - 5 2.16

2010

Public:

52.71

Public:

46.51

Public:

46.63
Company Name: Beximco Pharmaceuticals Ltd.

Company Information

Trading Code: BXPHARMA

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 23/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

2015-16*

2017
Financial Performance... (Continued)

Year

2014

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18453

86.5

4:00 PM

-0.4

-0.46%

86.9

86.9

86.9

86.4

86.30 - 87.90

20.826

84.50 - 113.50

240,765

513

35,242.86

9,100.00

4,055.56

10

405,556,445

Equity

Pharmaceuticals & Chemicals

Total Trade Graph:

For the year ended: Jun 30, 2017

12.5% 2017, 15% 2016


5% 2016, 5% 2014, 5% 2013, 15% 2012, 21% 2011, 20% 2010, 15% 2009, 20% 2008, 10% 2007, 10% 2006, 25% 2004,10% 2003, 15%
2002, 50% 97
Merger with Bx Infusion 2005,1:1 ( at premium Tk.325 )1992,1:1 ( at premium Tk.1100 )1994

30-Jun

15,744.80

2.6
Unaudited / Audited

Q1

Ending on

201709

4278.68

644.5

644.5

644.13

1.59

1.59

106.8

12-Aug-18

14.03

12-Aug-18

16.16

Year

2014

Jan'15-Dec'15

Jan'16-Jun'16

Jan'15-Jun'16

2017
Year

2014

Jan'15-Dec'15

Jan'16-Jun'16

Jan'15-Jun'16

2017

http://www.beximco-pharma.com/financial-reports.html
http://www.beximco-pharma.com/investor-relations/news-a-announcements.html

Sponsor/Director:

13.18

Sponsor/Director:

13.19

Sponsor/Director:

13.19

TK 1,190,203,818 Revaluation Surplus has been added to Reserve and Surplus.

Short-term loan (mn)

Long-term loan (mn)

Short-term

Long-term

17, Dhanmondi R/A, Road # 02, Dhaka - 1209

8611891 - 5, 8618220 - 7, 9677701 - 5


88 - 02 - 8613470, 8617647

csdbexim@bol-online.com

http://www.beximco-pharma.com
Total Volume Graph:
Q2 Half Yearly Q3 9 Months Annual

Ending on 6 Months Ending on 201803 Ending on

201712 201712 201803

4359.86 8638.54 4221.02 12859.56 -

672.92 1317.42 603.09 1920.51 -

672.92 1317.42 603.09 1920.51 -

673.19 1317.32 604.63 1921.95 -

1.66 3.25 1.49 4.74 -

- - - - -

1.66 3.25 1.49 4.74 -

- - - - -

103.8 103.8 102.8 102.8 -

13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

13.66 13.84 13.72 13.75 13.67

- - - - -

13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

15.72 15.94 15.79 15.83 15.74

- - - - -

Earnings per share(EPS) EPS - Continuing Operations Profit/(Loss) and OCI


NAV Per Share
Basic Basic
Diluted Diluted PCO* Profit for the year (mn)
Original Restated Original Restated Original Restated Diluted

- - - 4.15 - - 56.87 54.16 - 1528.3 -

- - - 5.06 - - 58.2 - - 1954.28 1954.28

- - - 2.57 - - - - - 993.77 993.77

- - - 7.63 7.27 - 59.7 56.86 - 2948.05 2948.05

- - - 5.49 - - 61.82 - - 2226.7 2226.7


Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %* Dividend Yield in %
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 14.82 - - 10.00, 5%B 1.7

- - - 16.62 - - - -

- - - 32.49 - - - -

- - - 10.94 11.49 - 15.00, 5%B 1.8

- - - 20.58 - - 12.5 1.11

1986

Govt: Institute: Foreign: Public:

0 24.01 41.45 21.36

Govt: Institute: Foreign: Public:

0 29.3 40.79 16.72

Govt: Institute: Foreign: Public:

0 29.7 40.05 17.06

Active

1239.76

2635.91

12.50 for 2017


(Loss) and OCI

TCI*

1953.93

993.11

2947.04

2229.27
Company Name: Beximco Synthetics Ltd.

Company Information

Trading Code: BXSYNTH

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 23/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

2015-16*

2017
Financial Performance... (Continued)

Year

2014

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18470

7.8

4:00 PM

0.00%

8.3

7.8

7.8

7.80 - 8.30

0.225

7.50 - 16.30

27,602

34

676.356

2,000.00

867.12

10

86,712,359

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

10% 2012, 15% 2011, 15% 2010, 7.5% 2009, 15% 2008, 10% 2007, 15% 2006, 10% 2005, 10% 2004,5% 2001

n/a

30-Jun

928.9

0
Unaudited / Audited

Q1 Q2 Half Yearly

Ending on Ending on 6 Months

201709 201712 201712

154.69 90.58 245.27

-31.28 -63.89 -95.16

-31.28 -63.89 -95.16

-31.28 -63.89 -95.16

-0.36 -0.74 -1.1

- - -

-0.36 -0.74 -1.1

- - -

8.5 8.9 8.9

12-Aug-18 13-Aug-18 14-Aug-18

- - -

- - -

12-Aug-18 13-Aug-18 14-Aug-18

n/a n/a n/a

- - -

Earnings per share(EPS)

Year Basic

Original Restated

2014 - -

Jan'15-Dec'15 - -

Jan'16-Jun'16 - -

Jan'15-Jun'16 - -

2017 - -
Year end Price Earnings (P/E) ratio

Earnings per share(EPS)


Year
Using Basic EPS

Original Restated

2014 - -

Jan'15-Dec'15 - -

Jan'16-Jun'16 - -

Jan'15-Jun'16 - -

2017 - -

1993

Sponsor/Director: Govt: Institute:

35.67 0 13.4

Sponsor/Director: Govt: Institute:

35.67 0 12.64

Sponsor/Director: Govt: Institute:

35.67 0 12.68

TK 1,329,335,883 Revaluation Surplus has been added to Reserve and Surplus.

Active

Short-term loan (mn) 517.94

Long-term loan (mn) 242.93

Short-term

Long-term

17, Dhanmondi, Road # 02, Dhaka - 1205

8611891 - 5, 8618220 - 7, 9677701 - 05


880 - 02 - 8613470, 8617647

beximchq@bol-online.com

http://www.beximco.org
Q3 9 Months Annual

Ending on 201803 Ending on

201803

925.02 1170.29 -

-118.27 -213.44 -

-118.27 -213.44 -

-118.27 -213.44 -

-1.36 -2.46 -

- - -

-1.36 -2.46 -

- - -

10.8 10.8 -

16-Aug-18 19-Aug-18 20-Aug-18

- - -

- - -

16-Aug-18 19-Aug-18 20-Aug-18

n/a n/a n/a

- - -

s per share(EPS) EPS - Continuing Operations Profit/(Loss) and OCI


NAV Per Share
Basic
Diluted Diluted PCO* Profit for the year (mn) TCI*
Original Restated Original Restated Diluted

- -0.31 - - 24.72 - - -26.56 - -

- -0.81 - - 23.71 - - -69.93 -69.93 -69.93

- -0.37 - - - - - -32.44 -32.44 -32.44

- -1.18 - - 23.34 - - -102.37 -102.37 -102.37

- -2.62 - - 20.71 - - -227.46 -227.46 -227.46


Year end Price Earnings (P/E) ratio

gs per share(EPS) EPS - Continuing Operations


Dividend in %* Dividend Yield in %
Using Using Basic EPS Using

Diluted EPS Original Restated Diluted EPS

- - - - - -

- - - - - -

- - - - - -

- - - - - -

- - - - - -

1993

Foreign: Public:

0.02 50.91

Foreign: Public:

0.02 51.67

Foreign: Public:

0.02 51.63
Company Name: Central Pharmaceuticals Limited

Company Information

Trading Code: CENTRALPHL

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 27/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2013

2014

2015

2016

2017
Financial Performance... (Continued)

Year

2013

2014

2015

2016

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18488

15.7

4:00 PM

0.4

2.61%

15.3

15.3

15.3

15.6

15.20 - 15.70

3.773

14.00 - 29.30

243,399

178

1,745.67

3,000.00

1,140.96

10

114,096,042

14 Aug, 2013

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

10% 2017, 10% 2016, 15% 2015, 15% 2014, 15% 2013

30-Jun

599.8

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

80.38 55.58 135.96 89.57 225.52 -

14.99 2.06 17.04 15.93 32.98 -

14.99 2.06 17.04 15.93 32.98 -

14.99 2.06 17.04 15.93 32.98 -

0.14 0.02 0.15 0.14 0.29 -

- - - - - -

0.14 0.02 0.15 0.14 0.29 -

- - - - - -

24.1 18.7 18.7 15.2 15.2 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

40.09 39.57 39.57 40.09 39.57 40.34

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

14.76 14.57 14.57 14.76 14.57 14.86

16.15 15.94 15.94 16.15 15.94 16.25

Earnings per share(EPS) EPS - Continuing Operations

Basic Basic
Diluted Diluted
Original Restated Original Restated

- - - 1.62 1.09 -

- - - 2.14 1.86 -

- - - 1.75 1.52 -

- - - 1.04 0.94 -

- - - 1.05 - -
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations

Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - - - -

- - - 18.76 18.76 -

- - - 15.89 18.29 -

- - - 16.44 18.19 -

- - - 28.81 - -

2013

Sponsor/Director: Govt: Institute: Foreign: Public:

30 0 13.36 0 56.64

Sponsor/Director: Govt: Institute: Foreign: Public:

25.89 0 13.21 0 60.9

Sponsor/Director: Govt: Institute: Foreign: Public:

25.89 0 12.62 0 61.49


1. One (01) year lock-in shares are treated as institutions category. 2. 514,848,089 Revaluation Reserve has been added to Reserve
& Surplus.

Active

Short-term loan (mn) 104.15

Long-term loan (mn) 106.23

10%B for 2017

Short-term

Long-term

2 A/1, South-West Darus Salam Road, Mirpur-1, Dhaka-1216

+88-02-7119404, 7119661
-9565906

info@centralphl.com

http://www.centralphl.com
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Original Restated Diluted

11.78 10.25 - 77.84 - -

20 17.39 - 152.26 - -

18.71 16.27 - 143.42 143.42 143.42

17.3 15.73 - 97.79 97.79 97.79

16.78 - - 109.09 109.09 109.09


Dividend in %* Dividend Yield in %

15%B -

5.00, 15%B 1.43

15%B -

10%B -

10%B -
Company Name: Far Chemical Industries Limited

Company Information

Trading Code: FARCHEM

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 20/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2013

2014

2015

2016

2017
Financial Performance... (Continued)

Year

2013

2014

2015

2016

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18490

18.2

4:00 PM

0.4

2.25%

17.9

17.8

17.8

18

17.70 - 18.20

18.334

15.40 - 25.90

1,020,404

650

3,208.32

3,000.00

1,802.42

10

180,242,498

08 Jul, 2014

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

5% 2016

10% 2017, 20% 2016, 25% 2015, 20% 2014

30-Jun

634.7

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

312.37 341.93 654.3 347.13 1001.43 -

75.47 73.53 149 67.56 216.56 -

75.47 73.53 149 67.56 216.56 -

75.47 73.53 149 67.56 216.56 -

0.46 0.41 0.83 0.37 1.2 -

- - - - - -

0.46 0.41 0.83 0.37 1.2 -

- - - - - -

23 19.5 19.5 15.7 15.7 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

11.69 11.44 11.25 11.5 11.13 11.25

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

10.45 10.22 10.06 10.28 9.94 10.06

11.54 11.3 11.11 11.36 10.99 11.11

Earnings per share(EPS) EPS - Continuing Operations

Basic Basic
Diluted Diluted
Original Restated Original Restated

- - - 5.01 4.35 -

3.45 - - 2.9 2.17 -

- - - 2.73 2.19 -

- - - 2.52 2.1 -

- - - 1.79 - -
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations

Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - - - -

- - - - - -

- - - 16.01 19.95 -

- - - 11.23 13.48 -

- - - 14.39 - -

2014

Sponsor/Director: Govt: Institute: Foreign: Public:

30.24 0 27.2 0 42.56

Sponsor/Director: Govt: Institute: Foreign: Public:

30.24 0 29.95 0 39.81

Sponsor/Director: Govt: Institute: Foreign: Public:

30.24 0 30.12 0 39.64

Active

Short-term loan (mn) 2

Long-term loan (mn) 0

10%B for 2017

Short-term

Long-term

House No: 11 (Floor: 5-A), Road No: 12, Niketon, Gulshan-1, Dhaka-1212

+88 02 9858734
+88 02 9858735

farchemicalltd@gmail.com

http://www.farchemicalbd.com
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Original Restated Diluted

15.55 14.81 - 395.58 - -

17.91 14.92 - 236.98 281.71 281.71

17.66 14.13 - 298.46 298.46 298.46

16.65 13.87 - 344.51 344.51 344.51

15.24 - - 292.61 292.61 292.61


Dividend in %* Dividend Yield in %

- -

20%B -

25%B -

5.00, 20%B 1.77

10%B -
Company Name: Global Heavy Chemicals Limited

Company Information

Trading Code: GHCL Scrip Code: 18485

Market Information: Aug 20, 2018

Last Trading Price 41.7

Last Update 4:00 PM

0.7
Change*
1.71%

Opening Price 41

Adjusted Opening Price 41

Yesterday's Closing Price 41

Closing Price 41.7

Day's Range 41.00 - 43.00

Day's Value (mn) 9.01

52 Weeks' Moving Range 36.10 - 56.90

Day's Volume (Nos.) 213,895

Day's Trade (Nos.) 286

Market Capitalization (mn) 2,952.00

Basic Information

Authorized Capital (mn) 1,000.00

Paid-up Capital (mn) 720

Face/par Value 10

Total No. of Outstanding Securities 72,000,000

Debut Trading Date 06 Mar, 2013

Type of Instrument Equity

Market Lot 1

Sector Pharmaceuticals & Chemicals

Closing Price Graph: Total Trade Graph:

Last AGM held on: 21/12/2017 For the year ended: Jun 30, 2017

Cash Dividend 10% 2017, 15% 2016, 10% 2014

Bonus Issue (Stock Dividend) -

Right Issue -

Year End 30-Jun

Reserve & Surplus without OCI (mn) 2,071.50

Other Comprehensive Income (OCI) (mn) 0


Interim Financial Performance: 2018

Unaudited / Audit

Q1
Particulars
Ending on

201709

Turnover/Revenue (mn) 139.52

Profit from continuing operations (mn) 18.87

Profit for the period (mn) 18.87

Total Comprehensive Income for the period (mn) 18.87

Earnings Per Share (EPS)

Basic 0.26

Diluted* -

Earnings Per Share (EPS) - continuing operations

Basic 0.26

Diluted* -

Market price per share at period end 42.2

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars 12-Aug-18

Current P/E Ratio using Basic EPS


38.45
(Continuing core operations)**

Current P/E ratio using Diluted EPS***


-
(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars 12-Aug-18

Current P/E Ratio using Basic EPS


41.3
(Continuing core operations)**

Current P/E ratio using Diluted EPS***


-
(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

Jan'15-Dec'15

2015-16* Jan'16-Jun'16

Jan'15-Jun'16

2017
Financial Performance... (Continued)

Year

2014

Jan'15-Dec'15

2015-16* Jan'16-Jun'16

Jan'15-Jun'16

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category A

Electronic Share Y

Sponsor/Director:
Share Holding Percentage [as on Jun 30, 2017 (year ended)]
69.03

Sponsor/Director:
Share Holding Percentage [as on Jun 30, 2018]
69.03

Sponsor/Director:
Share Holding Percentage [as on Jul 31, 2018]
69.03

Remarks 1. TK 1,525,671,614 Revaluation Reserve has been added to Rese

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Short-term loan (mn)

Long-term loan (mn)

Latest Dividend Status (%)

Latest Credit Rating Status

Short-term

Long-term

OTC/Delisting/Relisting

Address of the Company

Address 37, Segun Bagicha, Dhaka-1000

Contact Phone 880-2-9330191, 9357244


Fax 880-2-8312919

E-mail info.ghcl@opsonin.net

Web Address http://www.ghclbd.com


Total Volume Graph:
Unaudited / Audited

Q2 Half Yearly Q3 9 Months Annual

Ending on 6 Months Ending on 201803 Ending on

201712 201712 201803

151.93 291.45 143.77 435.23 -

22.47 41.34 21.64 62.98 -

22.47 41.34 21.64 62.98 -

22.47 41.34 21.64 62.98 -

0.31 0.57 0.3 0.87 -

- - - - -

0.31 0.57 0.3 0.87 -

- - - - -

39.7 39.7 37.1 37.1 -

13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

36.72 36.55 36.47 35.34 35.95

- - - - -

13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

39.44 39.26 39.17 37.96 38.61

- - - - -

Earnings per share(EPS) EPS - Continuing Operations Profit/(Loss) and OCI


NAV Per Share
Basic Basic
Diluted Diluted PCO* Profit for the year (mn)
Original Restated Original Restated Original Restated Diluted

- - - 1.95 - - 51.82 - - 140.21 140.21

- - - 1.24 - - 52.63 - - 89.39 89.39

- - - 0.57 - - - - - 41.02 41.02

- - - 1.81 - - 53.2 - - 130.4 130.4

- - - 1.08 - - 53.82 - - 78.07 78.07


Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %* Dividend Yield in %
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 21.54 - - 10 2.38

- - - 32.22 - - - -

- - - 68.46 - - - -

- - - 21.55 - - 15 3.85

- - - 36.89 - - 10 2.5

2013

Govt: Institute: Foreign: Public:

0 16.13 0 14.84

Govt: Institute: Foreign: Public:

0 20.46 0 10.51

Govt: Institute: Foreign: Public:

0 15.33 0 15.64

uation Reserve has been added to Reserve & Surplus.

Active

31.35

10.00 for 2017


(Loss) and OCI

TCI*

140.21

89.39

41.02

130.4

78.07
Company Name: GlaxoSmithKline(GSK) Bangladesh Ltd.

Company Information

Trading Code: GLAXOSMITH

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 19/04/2018

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2013

2014

2015

2016

2017
Financial Performance... (Continued)

Year

2013

2014

2015

2016

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Dec 31, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on December 31, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18454

1,131.90

4:00 PM

54.2

5.03%

1,084.00

1,077.70

1,077.70

1,129.60

1,083.00 - 1,134.90

0.274

1,005.00 - 1,700.10

243

42

12,982.46

200

120.46

10

12,046,449

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Dec 31, 2017

550% 2017, 500% 2016, 550% 2015

n/a

n/a

31-Dec

2,509.90

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3 Annual

Ending on Ending on 6 Months Ending on 9 Months Ending on

201803 201806 201806

1750.71 1626.63 3377.34 - - -

138.42 43.97 182.39 - - -

138.42 43.97 182.39 - - -

138.42 43.97 182.39 - - -

11.49 3.65 15.14 - - -

- - - - - -

11.49 3.65 15.14 - - -

- - - - - -

1452.8 1447.9 1447.9 - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

36.49 36.25 35.26 35.8 35.59 37.31

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

19.89 19.76 19.22 19.51 19.4 20.33

- - - - - -

Earnings per share(EPS) EPS - Continuing Operations

Year Basic Basic


Diluted
Original Restated Original Restated

2013 - - - 45.35 -

2014 - - - 68.63 -

2015 - - - 68.99 -

2016 - - - 53.51 -

2017 - - - 55.56 -
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Year
Using Basic EPS Using Using Basic EPS

Original Restated Diluted EPS Original Restated

2013 - - - 21.07 21.07

2014 - - - 22.03 22.03

2015 - - - 26.09 -

2016 - - - 28.65 -

2017 - - - 27.91 -

http://www.gsk.com.bd/publications/quarterly-reports.aspx
http://www.gsk.com.bd/investors/

1976

Sponsor/Director: Govt: Institute: Foreign: Public:

81.98 0 15.98 0.74 1.3

Sponsor/Director: Govt: Institute: Foreign: Public:

81.98 0 15.93 0.91 1.18

Sponsor/Director: Govt: Institute: Foreign: Public:

81.98 0 15.86 0.92 1.24

TK 59,479,000 Revaluation Reserve has been added to Reserve & Surplus.

Active

Short-term loan (mn) 0

Long-term loan (mn) 0

550.00 for 2017

Short-term

Long-term

House # 2A, Road # 138, Gulshan - 01, Dhaka - 1212

9858870-75
88 - 02 - 8826628

gsk.bangladesh-info@gsk.com

http://www.gsk.com.bd
S - Continuing Operations Profit/(Loss) and OCI
NAV Per Share

Diluted PCO* Profit for the year (mn) TCI*


Original Restated Diluted

- 153.66 - - 546.25 - -

- 192.3 - - 826.78 - -

- 216.15 - - 831.08 831.08 855.8

- 214.65 - - 644.55 644.55 644.55

- 218.35 - - 669.3 669.3 669.3


atio

S - Continuing Operations
Dividend in %* Dividend Yield in %
Using

Diluted EPS

- 300 3.14

- 420 2.78

- 550 3.06

- 500 3.26

- 550 3.55
Company Name: The IBN SINA Pharmaceutical Industry Ltd.

Company Information

Trading Code: IBNSINA

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 22/11/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

2015-16*

2017
Financial Performance... (Continued)

Year

2014

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18464

288

4:00 PM

4.7

1.66%

285

283.3

283.3

287.2

283.80 - 292.80

15.744

232.50 - 345.00

54,453

468

8,046.65

500

284

10

28,403,298

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

25% 2017, 37.50% 2016

10% 2017, 15% 2016, 5% 2014, 10% 2013, 20% 2012, 25% 2011, 20% 2010, 20% 2009

n/a

30-Jun

791.2

29.8
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months

Ending on Ending on 6 Months Ending on 201803

201709 201712 201712 201803

1235.41 1234.37 2469.78 1028.13 3497.91

61.76 107.14 169.11 48.28 217.38

61.76 107.14 169.11 48.28 217.38

84.55 128.02 212.77 -44.14 168.63

2.39 3.77 5.95 1.7 7.65

- - - - -

2.39 3.77 5.95 1.7 7.65

- - - - -

250.9 244.4 244.4 244.3 244.3

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18

28.75 27.93 27.45 27.54 27.77

- - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18

32.37 31.45 30.91 31 31.27

35.64 34.62 34.02 34.13 34.42

Earnings per share(EPS) EPS - Continuing Operations

Year Basic Basic


Diluted
Original Restated Original

2014 - - - 5.95

Jan'15-Dec'15 - - - 7.93

Jan'16-Jun'16 - - - 3.51

Jan'15-Jun'16 - - - 11.44

2017 - - - 9.06
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Year
Using Basic EPS Using Using Basic EPS

Original Restated Diluted EPS Original

2014 - - - 17.72

Jan'15-Dec'15 - - - 18.86

Jan'16-Jun'16 - - - 66.24

Jan'15-Jun'16 - - - 20.32

2017 - - - 27.37

1989

Sponsor/Director: Govt: Institute: Foreign: Public:

43.83 0 18.83 0 37.34

Sponsor/Director: Govt: Institute: Foreign: Public:

44.47 0 17.38 0 38.15

Sponsor/Director: Govt: Institute: Foreign: Public:

44.47 0 15.77 0 39.76

Active

Short-term loan (mn) 280.42

Long-term loan (mn) 229.5

25.00, 10%B for 2017

Short-term

Long-term

'Tanin Center' Plot-3, Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207

9114710, 9117496, 9132521


880 - 02 - 8118432, 8110315

ibnsina@bangla.net

http://www.ibnsinapharma.com
Annual

Ending on

20-Aug-18

28.16

20-Aug-18

31.7

34.9

EPS - Continuing Operations Profit/(Loss) and OCI


NAV Per Share
Basic
Diluted PCO* Profit for the year (mn) TCI*
Restated Original Restated Diluted

- - 31.77 30.26 - 127.28 - -

- - 37.1 - - 178.06 178.06 217.75

- - - - - 78.82 78.82 92.62

- - 38.72 - - 256.87 256.87 310.37

- - 42.79 - - 233.83 233.83 263.6


nings (P/E) ratio

EPS - Continuing Operations


Dividend in %* Dividend Yield in %
Using Basic EPS Using

Restated Diluted EPS

- - 30.00, 5%B 2.99

- - - -

- - - -

- - 37.50, 15%B 1.61

- - 25.00, 10%B 1.01


Company Name: Imam Button Industries Ltd.

Company Information

Trading Code: IMAMBUTTON

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 23/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2013

2014

2015

2016

2017
Financial Performance... (Continued)

Year

2013

2014

2015

2016

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18474

22.3

4:00 PM

0.7

3.24%

22.8

21.6

21.6

22.1

22.00 - 22.80

0.038

18.20 - 47.30

1,714

166.32

100

77

10

7,700,000

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

10%B 2010

n/a

30-Jun

-29.1

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

11.53 10.3 21.83 9.24 31.07 -

-1.17 -2.84 -4.02 -2.56 -6.58 -

-1.17 -2.84 -4.02 -2.56 -6.58 -

-1.17 -2.84 -4.02 -2.56 -6.58 -

-0.15 -0.37 -0.52 -0.33 -0.85 -

- - - - - -

-0.15 -0.37 -0.52 -0.33 -0.85 -

- - - - - -

22.4 35.6 35.6 31.4 31.4 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

- - - - - -

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

n/a n/a n/a n/a n/a n/a

- - - - - -

Earnings per share(EPS) EPS - Continuing Operations


NAV Per Share
Basic Basic
Diluted Diluted
Original Restated Original Restated Original

- - - -1.51 - - 4.16

- - - -1.81 - - 7.55

- - - -1.64 - - 9.31

- - - -1 - - 8.3

- - - -0.38 - - 6.22
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %*
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - - - - -

- - - - - - -

- - - - - - -

- - - - - - -

- - - - - - -

1996

Sponsor/Director: Govt: Institute: Foreign: Public:

31.53 0 15.38 0 53.09

Sponsor/Director: Govt: Institute: Foreign: Public:

31.53 0 9.01 0 59.46

Sponsor/Director: Govt: Institute: Foreign: Public:

31.53 0 9.01 0 59.46

Active

Short-term loan (mn) 0

Long-term loan (mn) 6.55

Short-term

Long-term

Amin Court (2'nd Floor), 62 - 63, Motijheel C/A, Dhaka - 1000.

9551837, 9558617
880 - 02 - 9564238

n/a

http://www.imambutton.com
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Restated Diluted

- - -11.62 - -

- - -13.9 - -

- - -12.63 -12.63 -12.63

- - -7.73 -7.73 -7.73

- - -2.89 -2.89 -2.89


Dividend Yield in %

-
Company Name: JMI Syringes & Medical Devices Ltd.

Company Information

Trading Code: JMISMDL

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 30/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

2015-16*

2017
Financial Performance... (Continued)

Year

2014

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18487

202.5

4:00 PM

5.7

2.90%

200

196.8

196.8

202.5

196.30 - 203.90

3.138

167.10 - 239.80

15,565

142

2,164.80

1,000.00

110

10

11,000,000

19 Jun, 2013

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

30% 2017, 35% 2016, 20% 2014

30-Jun

634

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

299.04 314.61 613.65 483.46 1097.1 -

8.62 15.26 23.88 22.22 46.1 -

8.62 15.26 23.88 22.22 46.1 -

8.62 15.26 23.88 22.22 46.1 -

0.78 1.39 2.17 2.02 4.19 -

- - - - - -

0.78 1.39 2.17 2.02 4.19 -

- - - - - -

190.2 181.4 181.4 176.9 176.9 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

34.67 35.05 36.46 36.98 35.23 36.25

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

28.57 28.88 30.04 30.47 29.03 29.87

- - - - - -

Earnings per share(EPS) EPS - Continuing Operations


NAV Per Share
Basic Basic
Diluted Diluted
Original Restated Original Restated Original

- - - 4.46 - - 48.86

Jan'15-Dec'15 - - - 4.81 - - 60.64

Jan'16-Jun'16 - - - 4.07 - - -

Jan'15-Jun'16 - - - 8.88 - - 64.63

- - - 6.78 - - 67.64
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %*
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 37.09 - - 20

Jan'15-Dec'15 - - - 35.26 - - -

Jan'16-Jun'16 - - - 36.34 - - -

Jan'15-Jun'16 - - - 16.64 - - 35

- - - 26.7 - - 30

2013

Sponsor/Director: Govt: Institute: Foreign: Public:

49.31 0 9.46 12.73 28.5

Sponsor/Director: Govt: Institute: Foreign: Public:

49.31 0 10.46 11.82 28.41

Sponsor/Director: Govt: Institute: Foreign: Public:

49.31 0 14.85 11.82 24.02

1. TK 402,102,104 Revaluation Reserve has been added to Reserve & Surplus.

Active

Short-term loan (mn) 375.17

Long-term loan (mn) 1171.95

30.00 for 2017

Short-term

Long-term

7/A Shantibag, Dhaka 1217

+880-2 9346630, 8318375, 9333102, 8318733


+880-2-9337798, 8318303

info@jmigroup-bd.com

http://www.jmisyringe.com
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Restated Diluted

- - 49.01 49.01 49.01

- - 52.95 52.95 52.95

- - 44.74 44.74 44.74

- - 97.69 97.69 97.69

- - 74.56 74.56 74.56


Dividend Yield in %

1.21

2.37

1.66
Company Name: Keya Cosmetics Ltd.

Company Information

Trading Code: KEYACOSMET

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 28/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2017

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2013

2014

2015

2016

2017
Financial Performance... (Continued)

Year

2013

2014

2015

2016

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18477

8.2

4:00 PM

0.2

2.50%

8.00 - 8.20

19.531

7.90 - 16.30

2,424,689

600

8,016.85

15,000.00

10,021.10

10

1,002,106,660

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

20% 2017, 18% 2016, 20% 2015, 20% 2014,10% 2013, 10% 2012, 21% 2011, 50% 2005

1R:1 2012, 1R:5 2007

30-Jun

2,807.90

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3

Ending on Ending on Ending on 9 Months


6 Months
201709

3015.46 - - - -

548.2 - - - -

548.2 - - - -

548.2 - - - -

0.66 - - - -

- - - - -

0.66 - - - -

- - - - -

14.2 - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18

3.03 3.03 3.03 3.07 3.03

- - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18

3.98 3.98 3.98 4.03 3.98

4.79 4.79 4.79 4.85 4.79

Earnings per share(EPS) EPS - Continuing Operations

Year Basic Basic


Diluted
Original Restated Original

2013 - - - 1.55

2014 - - - 1.51

2015 - - - 0.29

2016 - - - 1.87

2017 - - - 2.01
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Year
Using Basic EPS Using Using Basic EPS

Original Restated Diluted EPS Original

2013 - - - 19.79

2014 - - - 15.7

2015 - - - 67.93

2016 - - - 6.36

2017 - - - 7.33

2001

Sponsor/Director: Govt: Institute: Foreign: Public:

62.77 0 5.75 0 31.48

Sponsor/Director: Govt: Institute: Foreign: Public:

46.27 0 8.59 0 45.14

Sponsor/Director: Govt: Institute: Foreign: Public:

46.27 0 8.4 0 45.33

TK 468,576 Revaluation Reserve has been added to Reserve & Surplus.

Active

Short-term loan (mn) 0

Long-term loan (mn) 8598.51

20%B for 2017

Short-term

Long-term

Prio Prangon Tower,House No.19, Road No. 17, Kamal Ataturk Avenue, Banani, Dhaka-1213.

+88-02-9896973, 9899537
88 - 02 - 8831032

keyacosmetics@keya-bd.com

http://www.keyagroupbd.com/Keya-Cosmetics-Ltd
Annual

Ending on

20-Aug-18

3.03

20-Aug-18

3.98

4.79

EPS - Continuing Operations Profit/(Loss) and OCI


NAV Per Share
Basic
Diluted PCO* Profit for the year (mn) TCI*
Restated Original Restated Diluted

1.41 - 21.54 19.58 - 252.1 - -

0.46 - 21.09 13.37 - 270.1 270.1 270.1

0.24 - 16.67 13.89 - 169.7 169.7 169.7

1.59 - 15.77 13.36 - 1325.68 1325.68 1325.68

- - 15.37 - - 1675.04 1675.04 1675.04


nings (P/E) ratio

EPS - Continuing Operations


Dividend in %* Dividend Yield in %
Using Basic EPS Using

Restated Diluted EPS

19.79 - 10%B -

51.52 - 20%B -

82.08 - 20%B -

82.08 - 18%B -

- - 20%B -
Company Name: Kohinoor Chemicals Company (Bangladesh) Ltd.

Company Information

Trading Code: KOHINOOR

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 14/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2013

2014

2015

2016

2017
Financial Performance... (Continued)

Year

2013

2014

2015

2016

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18463

401.2

4:00 PM

3.9

0.98%

402

397.3

397.3

401.9

396.10 - 402.00

0.661

365.00 - 482.00

1,652

49

5,568.41

500

140.16

10

14,015,625

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

15% 2017, 10% 2016, 30% 2015

15% 2017, 20% 2016, 25% 2014, 25% 2013, 30% 2012

n/a

30-Jun

413.9

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

902.79 1004.01 1906.8 963.65 2870.45 -

36.95 35.4 72.35 35.08 107.43 -

36.95 35.4 72.35 35.08 107.43 -

36.95 35.4 72.35 35.08 107.43 -

3.03 2.53 5.16 2.5 7.66 -

- - - - - -

3.03 2.53 5.16 2.5 7.66 -

- - - - - -

421 382.8 382.8 366.7 366.7 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

39.42 39.29 38.85 39.35 38.9 39.35

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

33.44 33.33 32.96 33.38 33 33.38

38.45 38.33 37.9 38.39 37.95 38.39

Earnings per share(EPS) EPS - Continuing Operations


NAV Per Share
Basic Basic
Diluted Diluted
Original Restated Original Restated Original

- - - 14.33 11.46 - 18.16

- - - 13.2 10.56 - 29.19

- - - 9.01 - - 32.35

- - - 11.75 9.79 - 41.1

- - - 12.04 - - 45.46
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %*
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 20.94 20.94 - 25%B

- - - 37.41 37.41 - 25%B

- - - 39.28 - - 30

- - - 30.31 36.37 - 10.00, 20%B

- - - 34.67 - - 15.00, 15%B

http://www.kohinoor-bd.com/finance/

1988

Sponsor/Director: Govt: Institute: Foreign: Public:

48.72 0 16.18 0 35.1

Sponsor/Director: Govt: Institute: Foreign: Public:

48.72 0 14.38 0 36.9

Sponsor/Director: Govt: Institute: Foreign: Public:

48.72 0 14.38 0 36.9

TK 7,143,605 Revaluation Reserve has been added to Reserve & Surplus.

Active

Short-term loan (mn) 30.89

Long-term loan (mn) 326.09

15.00, 15%B for 2017

Short-term

Long-term

36, Shahid Tajuddin Ahmed Sarani , Tejgaon I/A, Dhaka -


1208
880-2-8891267-70
88 - 02 - 8891523

info@kccl-bd.com

http://www.kohinoor-bd.com
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Restated Diluted

14.53 - 93.13 - -

23.35 - 107.22 - -

- - 91.46 91.46 91.46

34.25 - 119.3 119.3 119.3

- - 146.8 146.8 146.8


Dividend Yield in %

0.85

0.28

0.36
Company Name: Libra Infusions Limited

Company Information

Trading Code: LIBRAINFU

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 20/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS


Year

2013

2014

2015

2016

2017

Financial Performance... (Continued)

Year

2013

2014

2015

2016

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)


Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone

Fax

E-mail

Web Address
Scrip Code: 18471

681.2

4:00 PM

10.5

1.57%

670.7

670.7

670.7

672

650.00 - 692.60

3.64

480.00 - 1,334.80

5,387

308

839.448

100

12.52

10

1,251,600

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

30% 2017, 25% 2016, 20% 2015

n/a

n/a

30-Jun

1,962.50

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

50.28 69.86 120.14 21.33 141.47 -

0.05Mismatch is due -15.83Mismatch is due

-8.81 6.13 to issuer's own -15.18 to issuer's own -

actual disclosure actual disclosure

0.05Mismatch is due -15.83Mismatch is due

-8.81 6.13 to issuer's own -15.83 to issuer's own -

actual disclosure actual disclosure

0.05Mismatch is due -15.83Mismatch is due

-8.81 6.13 to issuer's own -15.83 to issuer's own -

actual disclosure actual disclosure

0.040Mismatch is due -12.650Mismatch is due

-7.04 4.9 to issuer's own -12.13 to issuer's own -

actual disclosure actual disclosure

- - - - - -

0.040Mismatch is due -12.650Mismatch is due

-7.04 4.9 to issuer's own -12.13 to issuer's own -

actual disclosure actual disclosure

- - - - - -

558 523 523 537.4 537.4 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

- - - - - -

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

155.91 162 153.68 149.14 138 138.27

- - - - - -
Earnings per share(EPS) EPS - Continuing Operations

Basic Basic
Diluted
Original Restated Original Restated

- - - 4.21 -

- - - 5.92 -

- - - 3.44 -

- - - 4.65 -

- - - 4.86 -

Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations

Using Basic EPS Using Using Basic EPS

Original Restated Diluted EPS Original Restated

- - - 56.41 56.41

- - - 70.57 70.57

- - - 98.02 -

- - - 130.54 -

- - - 107.37 -

1994

Sponsor/Director: Govt: Institute: Foreign: Public:

34.43 0 13.86 0 51.71

Sponsor/Director: Govt: Institute: Foreign: Public:

34.43 0 13.86 0 51.71

Sponsor/Director: Govt: Institute: Foreign: Public:

34.43 0 13.86 0 51.71

Tk 1,885,327,646 has been added to shareholders equity representing Revaluation Surplus.

Active

Short-term loan (mn) 0

Long-term loan (mn) 57.68

30.00 for 2017


Short-term

Long-term

I/7, Mirpur I/E (Rupnogor), Section # 2, Mirpur Dhaka - 1216.

8012536, 8012534, 9004770 - 71

88 - 02 - 8015833

n/a

http://www.libragroupbd.com
ntinuing Operations Profit/(Loss) and OCI
NAV Per Share

Diluted PCO* Profit for the year (mn) TCI*


Original Restated Diluted

- 1567.58 - - 5.27 - -

- 1571.5 - - 7.41 - -

- 1572.95 - - 4.31 4.31 4.31

- 1575.6 - - 5.82 5.82 5.82

- 1577.96 - - 6.09 6.09 6.09

ntinuing Operations
Dividend in %* Dividend Yield in %
Using

Diluted EPS

- 20 0.84

- 20 0.48

- 20 0.59

- 25 0.41

- 30 0.57
Company Name: Marico Bangladesh Limited

Company Information

Trading Code: MARICO

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 18/07/2018

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

2015

2016

2017

2018
Financial Performance... (Continued)

Year

2014

2015

2016

2017

2018

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Mar 31, 2018 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on March 31, 2018

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18481

1,130.00

4:00 PM

-6.7

-0.59%

1,140.00

1,136.70

1,136.70

1,130.50

1,130.00 - 1,140.00

0.687

1,010.00 - 1,293.70

608

18

35,806.05

400

315

10

31,500,000

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Mar 31, 2018

600% 2018, 500% 2017, 450% 2016, 425% 2015

31-Mar

923.2

2.4
Unaudited / Audited

Q1 Q2

Ending on Ending on

201806

2470.04 -

554.93 -

554.93 -

554.93 -

17.62 -

- -

17.62 -

- -

1160 -

12-Aug-18 13-Aug-18

16.06 15.91

- -

12-Aug-18 13-Aug-18

21.71 21.51

- -

Earnings per share(EPS)

Year Basic

Original

2014 -

2015 -

2016 -

2017 -

2018 -
Year end Price Earnings (P/

Earnings per share(EPS)


Year
Using Basic EPS

Original

2014 -

2015 -

2016 -

2017 -

2018 -

http://marico.com/bangladesh/investors/documentation/quarterly-updates
http://marico.com/bangladesh/investors/documentation/price-sensitive-information

Sponsor/Director: Govt:

90 0

Sponsor/Director: Govt:

90 0

Sponsor/Director: Govt:

90 0

Active

Short-term loan (mn) 300

Long-term loan (mn) 0

600.00 for 2018

Short-term

Long-term

House No. 01, Road No. 01, Sector No. 01, Uttara, Dhaka 1230

8931202
8932322

info@maricobangladesh.net

http://marico.com/bangladesh
Half Yearly Q3 Annual

Ending on 9 Months Ending on


6 Months

- - - -

- - - -

- - - -

- - - -

- - - -

- - - -

- - - -

- - - -

- - - -

14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

16.19 16.14 16.13 16.04

- - - -

14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

21.88 21.82 21.8 21.68

- - - -

Earnings per share(EPS) EPS - Continuing Operations Profit/(Loss) and OCI


NAV Per Share
Basic Basic
Diluted Diluted PCO* Profit for the year (mn) TCI*
Restated Original Restated Original Restated Diluted

- - 43.99 - - 54.16 - - 1385.61 - -

- - 42.69 - - 54.35 - - 1344.77 1344.77 1344.77

- - 44.89 - - 54.25 - - 1414.05 1414.05 1414.05

- - 45.72 - - 50.16 - - 1440.19 1440.19 1447.7

- - 52.15 - - 47.38 - - 1642.63 1642.63 1644.98


Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %* Dividend Yield in %
Using Basic EPS Using Using Basic EPS Using

Restated Diluted EPS Original Restated Diluted EPS

- - 25.63 25.63 - 900 7.98

- - 33.54 - - 425 2.97

- - 28.07 - - 450 3.57

- - 22.01 - - 500 4.97

- - 23.29 - - 600 4.94

2009

Institute: Foreign: Public:

2.81 6.4 0.79

Institute: Foreign: Public:

2.74 6.53 0.73

Institute: Foreign: Public:

2.74 6.53 0.73


Company Name: Orion Infusion Ltd.

Company Information

Trading Code: ORIONINFU

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 14/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2013

2014

2015

2016

2017
Financial Performance... (Continued)

Year

2013

2014

2015

2016

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18472

52.6

4:00 PM

0.9

1.74%

52.2

51.7

51.7

52.2

51.70 - 52.80

1.777

45.10 - 68.90

33,946

131

1,052.60

1,000.00

203.59

10

20,359,760

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

14% 2017, 14% 2016, 13% 2015

1:1R 1996

30-Jun

45.2

7.1
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

167.9 181.32 349.22 123.53 472.75 -

7.46 8.61 16.08 4.94 21.02 -

7.46 8.61 16.08 4.94 21.02 -

7.44 8.66 16.1 3.35 19.45 -

0.37 0.42 0.79 0.24 1.03 -

- - - - - -

0.37 0.42 0.79 0.24 1.03 -

- - - - - -

58.9 55.5 55.5 52.9 52.9 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

39.39 38.16 37.65 38.59 37.65 38.01

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

35.36 34.25 33.79 34.64 33.79 34.12

- - - - - -

Earnings per share(EPS) EPS - Continuing Operations


NAV Per Share
Basic Basic
Diluted Diluted
Original Restated Original Restated Original

- - - 1.27 - - 7

- - - 3.64 - - 8.15

- - - 1.39 - - 9.21

- - - 5.25 - - 12.98

- - - 1.53 - - 12.57
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %*
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 33.39 33.39 - 12

- - - 12.25 12.25 - 15

- - - 31.29 - - 13

- - - 13.73 - - 14

- - - 37.83 - - 14

1994

Sponsor/Director: Govt: Institute: Foreign: Public:

40.61 0 21.64 0.26 37.49

Sponsor/Director: Govt: Institute: Foreign: Public:

40.61 0 26.02 0.14 33.23

Sponsor/Director: Govt: Institute: Foreign: Public:

40.61 0 25.79 0.14 33.46

TK 145,602,454 Revaluation Surplus has been added to Reserve & Surplus.

Active

Short-term loan (mn) 323.89

Long-term loan (mn) 0

14.00 for 2017

Short-term

Long-term

Orion House (2nd Floor), 153-154, Tejgaon 1/A, Dhaka-1208.

+88-02-8870133, 8870134, 9888494, 9888176, 9898124


880-02-8870130

orion@bol-online.com

http://www.orioninfusion.com
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Restated Diluted

- - 25.94 - -

- - 74.1 - -

- - 28.25 28.25 28.25

- - 106.98 106.98 111.6

- - 31.11 31.11 38.2


Dividend Yield in %

2.83

3.36

2.99

1.94

2.42
Company Name: Orion Pharma Ltd.

Company Information

Trading Code: ORIONPHARM

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 14/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2012

2013

2014

2015-16*

2017
Financial Performance... (Continued)

Year

2012

2013

2014

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18486

38.8

4:00 PM

0.3

0.78%

38.5

38.5

38.5

38.7

38.40 - 39.20

3.965

37.70 - 51.80

102,832

81

9,009.00

5,000.00

2,340.00

10

234,000,000

20 Mar, 2013

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

15% 2017, 15% 2016, 15% 2014

20% 2012

30-Jun

6,315.20

-69.5
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

2857.98 2243.91 5101.89 2548.76 7650.64 -

257.54 227.98 485.51 160.35 645.87 -

257.54 227.98 485.51 160.35 645.87 -

255.7 210.03 465.73 140.77 606.49 -

1.1 0.97 2.07 0.69 2.76 -

- - - - - -

1.1 0.97 2.07 0.69 2.76 -

- - - - - -

47.9 48.7 48.7 47.8 47.8 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

10.71 10.35 10.49 10.6 10.46 10.52

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

11.59 11.21 11.35 11.47 11.32 11.38

- - - - - -

Earnings per share(EPS) EPS - Continuing Operations


NAV Per Share
Basic Basic
Diluted Diluted
Original Restated Original Restated Original

- - - 6.02 3.99 - 82.42

- - - 4.06 - - 65.23

- - - 4.25 - - 67.5

Jan'15-Jun'16 - - - 5.65 - - 69.99

- - - 3.4 - - 70.95
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %*
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - - - - 20.00, 20%B

- - - 14.46 14.46 - 15

- - - 10.71 - - 15

Jan'15-Jun'16 - - - 6.51 - - 15

- - - 14.96 - - 15

2013

Sponsor/Director: Govt: Institute: Foreign: Public:

31.98 0 40.95 4.04 23.03

Sponsor/Director: Govt: Institute: Foreign: Public:

31.98 0 46.83 4 17.19

Sponsor/Director: Govt: Institute: Foreign: Public:

31.98 0 47.11 4 16.91

TK 1,795,623,161 Revaluation Reserve has been added to Reserve & Surplus.

Active

Short-term loan (mn) 1829.11

Long-term loan (mn) 4428.29

15.00 for 2017

Short-term

Long-term

Orion House, 153-154, Tejgaon I/A,Dhaka-1208.

+ 88 02 8870130, 8870133, 8870134, 9888176, 8822543


+88 02 8870108, 8870130

orion@bol-online.com

http://www.orionpharmabd.com
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Restated Diluted

64.85 - 933.04 - -

- - 908.86 - -

- - 994.09 994.09 992.111

- - 1323.07 1323.07 1323.07

- - 794.5 794.5 724.96


Dividend Yield in %

2.56

3.3

4.08

2.95
Company Name: Pharma Aids

Company Information

Trading Code: PHARMAID

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 28/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2013

2014

2015

2016

2017
Financial Performance... (Continued)

Year

2013

2014

2015

2016

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18462

546.3

4:00 PM

2.9

0.53%

543.4

543.4

543.4

545

542.50 - 553.90

13.929

262.30 - 707.00

25,452

656

1,695.41

50

31.2

10

3,120,000

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

35% 2017, 30% 2016, 25% 2015

500% 2010

n/a

30-Jun

123.3

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

53.18 65.98 119.16 59.75 178.9 -

11.85 13.28 25.12 13.39 38.51 -

11.85 13.28 25.12 13.39 38.51 -

11.85 13.28 25.12 13.39 38.51 -

3.8 4.26 8.05 4.29 12.34 -

- - - - - -

3.8 4.26 8.05 4.29 12.34 -

- - - - - -

273.9 418.3 418.3 464.4 464.4 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

34.2 34.75 34.39 34.25 33.03 33.12

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

59.36 60.32 59.68 59.45 57.32 57.49

- - - - - -

Earnings per share(EPS) EPS - Continuing Operations


NAV Per Share
Basic Basic
Diluted Diluted
Original Restated Original Restated Original

- - - 1.39 - - 26.19

- - - 5.58 - - 31.76

- - - 8.16 - - 37.43

- - - 7.52 - - 42.45

- - - 9.48 - - 49.53
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %*
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 127.63 127.63 - 15

- - - 34.16 34.16 - 25

- - - 30.72 - - 25

- - - 28.99 - - 30

- - - 28.86 - - 35

1987

Sponsor/Director: Govt: Institute: Foreign: Public:

28.44 0 5.85 0 65.71

Sponsor/Director: Govt: Institute: Foreign: Public:

24.22 0 3.38 0 72.4

Sponsor/Director: Govt: Institute: Foreign: Public:

24.22 0 3.38 0 72.4

Active

Short-term loan (mn) 1.65

Long-term loan (mn) 3.8

35.00 for 2017

Short-term

Long-term

345, Segun Bagicha (1st Floor), Ramna, Dhaka - 1000

(8802) 9337741 - 43, 8316481, 8322001


88- 02 - 8313538, 8313687, 9338414

pal@excelsiorbd.net

http://www.pharmaaids.com
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Restated Diluted

- - 4.33 - -

- - 17.4 - -

- - 25.47 25.47 25.47

- - 23.47 23.47 23.47

- - 29.57 29.57 29.57


Dividend Yield in %

0.85

1.31

1.38

1.28
Company Name: Reckitt Benckiser(Bd.)Ltd.

Company Information

Trading Code: RECKITTBEN

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 25/06/2018

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2013

2014

2015

2016

2017
Financial Performance... (Continued)

Year

2013

2014

2015

2016

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Dec 31, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on December 31, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18460

1,688.00

4:00 PM

-12

-0.71%

1,734.00

1,700.00

1,700.00

1,696.00

1,672.00 - 1,734.00

1.314

1,470.20 - 2,280.00

772

28

8,032.50

250

47.25

10

4,725,000

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Dec 31, 2017

790% 2017, 775% 2016, 650% 2015

1B:4 96, 1B:2 88, 1B:2 86

n/a

31-Dec

263

-6.5
Unaudited / Audited

Q1 Q2 Half Yearly Q3 Annual

Ending on Ending on 6 Months Ending on 9 Months Ending on

201803 201806 201806

949.1 923.98 1873.08 - - -

34.7 56.84 91.54 - - -

34.7 56.84 91.54 - - -

34.7 56.84 91.54 - - -

7.34 12.03 19.37 - - -

- - - - - -

7.34 12.03 19.37 - - -

- - - - - -

1906.7 1801.3 1801.3 - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

43.9 44.14 43.87 43.88 43.88 43.78

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

21.09 21.21 21.08 21.08 21.08 21.03

- - - - - -

Earnings per share(EPS) EPS - Continuing Operations

r Basic Basic
Diluted Diluted
Original Restated Original Restated

3 - - - 27.42 - -

4 - - - 37.57 - -

5 - - - 58.73 - -

6 - - - 62.66 - -

7 - - - 80.63 - -
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


r
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

3 - - - 31.73 31.73 -

4 - - - 28.92 - -

5 - - - 27.4 - -

6 - - - 24.74 - -

7 - - - 22.03 - -

http://www.rb.com/Investors-media/rb-bangladesh

1987

Sponsor/Director: Govt: Institute: Foreign: Public:

82.96 3.77 5.95 2.7 4.62

Sponsor/Director: Govt: Institute: Foreign: Public:

82.96 3.77 5.94 2.7 4.62

Sponsor/Director: Govt: Institute: Foreign: Public:

82.96 3.77 5.95 2.95 4.37

Active

Short-term loan (mn) 0

Long-term loan (mn) 0

790.00 for 2017

Short-term

Long-term

Plot # 2(B), Block # SE(C), Road # 138, Gulshan - 1, Dhaka - 1212

(8802) 9887209
88 - 02 - 9887354

N/A

http://www.rb.com/rb-worldwide
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Original Restated Diluted

91.3 - - 129.54 - -

44.75 - - 177.54 - -

43.48 - - 277.51 277.51 277.51

50.02 - - 296.09 296.09 290.8

64.28 - - 381 381 374.48


Dividend in %* Dividend Yield in %

400 4.6

550 5.06

650 4.04

775 5

790 4.45
Company Name: Renata Ltd.

Company Information

Trading Code: RENATA

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 09/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

2015-16*

2017
Financial Performance... (Continued)

Year

2014

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18457

1,230.00

4:00 PM

-0.9

-0.07%

1,230.00

1,230.90

1,230.90

1,229.30

1,220.00 - 1,232.00

2.494

1,055.00 - 1,320.60

2,031

109

86,201.19

1,000.00

700.31

10

70,031,022

Equity

Pharmaceuticals & Chemicals

Total Trade Graph:

For the year ended: Jun 30, 2017

130% 2017, 85% 2016


15% 2017, 15% 2016, 20% 2014, 25% 2013, 25% 2012, 25%B 2011, 25% 2010, 25% 2009, 25% 2008, 20% 2007, 20% 2006, 20% 2005,
20% 2004,20% 2003, 10% 1997
n/a

30-Jun

12,224.40

18.2
Unaudited / Audited

Q1

Ending on

201709

4657.02

712.41

712.41

712.41

11.62

11.62

1164.9

12-Aug-18

29.73

12-Aug-18

28.07

32.28

Year

2014

Jan'15-Dec'15

Jan'16-Jun'16

Jan'15-Jun'16

2017
Year

2014

Jan'15-Dec'15

Jan'16-Jun'16

Jan'15-Jun'16

2017

http://www.renata-ltd.com/DSE/Financial%20Statements.pdf
http://www.renata-ltd.com/DSE/Price%20Sensitive.pdf

Sponsor/Director:

51.16

Sponsor/Director:

51.16

Sponsor/Director:

51.16

TK 155,285,034 Revaluation Reserve has been added to Reserve & Surplus.

Short-term loan (mn)

Long-term loan (mn)

Short-term

Long-term

Plot # 1, Milk Vita Road, Section-7, Mirpur, Dhaka - 1216.

8001450, 8001454
880-2-8001446

renata@renata-ltd.com

http://www.renata-ltd.com
Total Volume Graph:
Q2 Half Yearly Q3 9 Months Annual

Ending on 6 Months Ending on 201803 Ending on

201712 201712 201803

4681.41 9338.43 4600.7 13939.13 -

708.24 1420.65 774.59 2195.24 -

708.24 1420.65 774.59 2195.24 -

708.24 1420.65 774.59 2195.24 -

9.98 20.08 11.06 31.14 -

- - - - -

9.98 20.08 11.06 31.14 -

- - - - -

1124.2 1124.2 1233.9 1233.9 -

13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

29.67 29.66 29.42 29.65 29.61

- - - - -

13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

28.01 28 27.77 27.99 27.95

32.21 32.2 31.94 32.19 32.15

Earnings per share(EPS) EPS - Continuing Operations Profit/(Loss) and OCI


NAV Per Share
Basic Basic
Diluted Diluted PCO* Profit for the year (mn)
Original Restated Original Restated Original Restated Diluted

- - - 38.24 - - 181.04 150.86 - 1687.49 -

- - - 39.21 - - 183.5 - - 2076.49 2076.49

- - - 23.2 - - - - - 1228.42 1228.42

- - - 62.59 54.43 - 206.61 179.66 - 3314.35 3314.35

- - - 43.98 - - 212.54 - - 2678.06 2678.06


Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %* Dividend Yield in %
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 30.88 - - 80.00, 20%B 0.81

- - - 31.45 - - - -

- - - 51.09 - - - -

- - - 18.94 21.78 - 85.00, 15%B 0.72

- - - 26.31 - - 130.00, 15%B 1.12

1979

Govt: Institute: Foreign: Public:

0 17.18 21.78 9.88

Govt: Institute: Foreign: Public:

0 16.63 22.03 10.18

Govt: Institute: Foreign: Public:

0 18.07 22.29 8.48

Active

1972.45

95.91

130.00, 15%B for 2017


(Loss) and OCI

TCI*

2081.18

1223.62

3314.25

2696.28
Company Name: Salvo Chemical Industry Limited

Company Information

Trading Code: SALVOCHEM

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 06/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

2015-16*

2017
Financial Performance... (Continued)

Year

2014

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18484

26.2

4:00 PM

0.8

3.15%

25.2

25.4

25.4

26.1

25.20 - 26.50

7.105

18.30 - 30.90

275,280

147

1,572.93

1,500.00

619.26

10

61,926,471

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

5% 2017, 5% 2016, 10% 2014, 10% 2013, 5% 2012, 5% 2011, 5% 2010

30-Jun

83.1

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

78.78 61.49 140.27 84.82 225.09 -

13.87 6.47 20.34 16.6 36.94 -

13.87 6.47 20.34 16.6 36.94 -

13.87 6.47 20.34 16.6 36.94 -

0.24 0.1 0.33 0.27 0.6 -

- - - - - -

0.24 0.1 0.33 0.27 0.6 -

- - - - - -

21.7 21.6 21.6 25.7 25.7 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

33.88 33.63 33.13 32.38 31.75 32.63

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

34.3 34.05 33.54 32.78 32.15 33.04

35.66 35.39 34.87 34.08 33.42 34.34

Earnings per share(EPS) EPS - Continuing Operations

Basic Basic
Diluted Diluted
Original Restated Original Restated

- - - 1.13 - -

Jan'15-Dec'15 - - - 0.62 - -

Jan'16-Jun'16 - - - 0.39 - -

Jan'15-Jun'16 - - - 1 0.95 -

- - - 0.79 - -
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations

Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 18.32 - -

Jan'15-Dec'15 - - - 20.79 - -

Jan'16-Jun'16 - - - 30.52 - -

Jan'15-Jun'16 - - - 11.8 12.42 -

- - - 29.63 - -

2011

Sponsor/Director: Govt: Institute: Foreign: Public:

22.14 0 14.03 0 63.83

Sponsor/Director: Govt: Institute: Foreign: Public:

22.14 0 9.32 0 68.54

Sponsor/Director: Govt: Institute: Foreign: Public:

22.14 0 11.16 0 66.7

Active

Short-term loan (mn) 97.48

Long-term loan (mn) 49.84

5%B for 2017

Short-term

Long-term

Suite No. 401, (3rd Floor), 210-211, Nawabpur Road, Dhaka-1100

88-02-7162135, 7124767
88-02-7161661

salvoheadoffice@yahoo.com

http://www.salvochemical.com
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Original Restated Diluted

11.74 - - 57.54 57.54 57.54

11.28 - - 34.58 34.58 34.58

- - - 21.72 21.72 21.72

11.67 11.12 - 56.29 56.29 56.29

11.91 - - 46.78 46.78 46.78


Dividend in %* Dividend Yield in %

10%B -

- -

- -

5%B -

5%B -
Company Name: Square Pharmaceuticals Ltd.

Company Information

Trading Code: SQURPHARMA

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 04/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2015

2015-16*
2015-16*

2017

Financial Performance... (Continued)

Year

2015

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company


Address

Contact Phone

Fax

E-mail

Web Address
Scrip Code: 18473

275.9

4:00 PM

-0.5

-0.18%

276.3

276.4

276.4

276.2

275.30 - 280.90

55.548

263.00 - 335.00

200,506

1,079

203,814.90

10,000.00

7,373.91

10

737,391,090

Equity

Pharmaceuticals & Chemicals

Total Trade Graph:

For the year ended: Jun 30, 2017

35% 2017, 40% 2016, 30% 2015


7.5% 2017, 10% 2016, 12.50% 2015, 15% 2014, 30% 2013, 40% 2012, 35% 2011, 30% 2010, 25% 2009, 35% 2008, 50% 2007, 20%2006,
15% 2005, 20% 2004,20% 2003, 20% 2002, 25% 96
-

30-Jun

39,288.60

329.8
Unaudited / Audited

Q1

Ending on

201709

9867.95

3008.43

3008.43

3254.77

4.39

4.39

306

12-Aug-18

16.88

12-Aug-18

17.4

18.7

Year

2015

Apr'15-Mar'16

Apr'16-Jun'16
Apr'15-Jun'16

2017

Year

2015

Apr'15-Mar'16

Apr'16-Jun'16

Apr'15-Jun'16

2017

http://www.squarepharma.com.bd/splpsi.php
http://www.squarepharma.com.bd/splpsi.php

Sponsor/Director:

36.34

Sponsor/Director:

34.43

Sponsor/Director:

34.43

Short-term loan (mn)

Long-term loan (mn)

Short-term

Long-term
Square Centre, 48, Mohakhali C/A, Dhaka - 1212

8833047-56, 8859007

88 - 02 - 8828768

info@squaregroup.com

http://www.squarepharma.com.bd
Total Volume Graph:
Q2 Half Yearly Q3 9 Months Annual

Ending on 6 Months Ending on 201803 Ending on

201712 201712 201803

29572.54Mismatch is due

9852.69 19720.64 11386.48 to issuer's own -

actual disclosure

2855.96 5864.39 2975.82 8840.21 -

2855.96 5864.39 2975.82 8840.21 -

2704.01 5958.78 2533.33 8492.12 -

3.87 7.95 4.04 11.99 -

- - - - -

3.87 7.95 4.04 11.99 -

- - - - -

301.8 301.8 310 310 -

13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

16.67 17.15 17.08 17.29 17.28

- - - - -

13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

17.18 17.68 17.6 17.82 17.81

18.47 19 18.92 19.15 19.14

Earnings per share(EPS) EPS - Continuing Operations Profit/(Loss) and OCI


NAV Per Share
Basic Basic
Diluted Diluted PCO*
Original Restated Original Restated Original Restated Diluted

- - - 10.8 9.6 - 56.09 49.86 - 5983.81

- - - 13.34 - - 61.01 - - 8321.27

- - - 3.84 - - - - - 2394.58
- - - 17.18 15.62 - 65.04 59.13 - 10715.86

- - - 15.51 - - 71.47 - - 10637.22

Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %* Dividend Yield in %
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 24.36 27.41 - 30.00, 12.50%B 1.14

- - - 18.79 - - - -

- - - 69.19 - - - -

- - - 15.47 17.01 - 40.00, 10%B 0.38

- - - 18.71 - - 35.00, 7.5%B 1.21

1995

Govt: Institute: Foreign: Public:

0 9.82 19.75 34.09

Govt: Institute: Foreign: Public:

0 10.12 19.85 35.6

Govt: Institute: Foreign: Public:

0 10.06 19.69 35.82

Active

1700.3

35.00, 7.5%B for 2017


Profit/(Loss) and OCI

Profit for the year (mn) TCI*

5983.81 5983.81

8321.27 8331.89

2394.58 2385.42
10715.86 10717.31

10637.22 10966.99
Company Name: Wata Chemicals Limited

Company Information

Trading Code: WATACHEM

Market Information: Aug 20, 2018

Last Trading Price

Last Update

Change*

Opening Price

Adjusted Opening Price

Yesterday's Closing Price

Closing Price

Day's Range

Day's Value (mn)

52 Weeks' Moving Range

Day's Volume (Nos.)

Day's Trade (Nos.)

Market Capitalization (mn)

Basic Information

Authorized Capital (mn)

Paid-up Capital (mn)

Face/par Value

Total No. of Outstanding Securities

Debut Trading Date

Type of Instrument

Market Lot

Sector

Closing Price Graph:

Last AGM held on: 21/12/2017

Cash Dividend

Bonus Issue (Stock Dividend)

Right Issue

Year End

Reserve & Surplus without OCI (mn)

Other Comprehensive Income (OCI) (mn)


Interim Financial Performance: 2018

Particulars

Turnover/Revenue (mn)

Profit from continuing operations (mn)

Profit for the period (mn)

Total Comprehensive Income for the period (mn)

Earnings Per Share (EPS)

Basic

Diluted*

Earnings Per Share (EPS) - continuing operations

Basic

Diluted*

Market price per share at period end

Price Earnings (P/E) Ratio based on latest Un-audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Price Earnings (P/E) Ratio Based on latest Audited Financial Statements

Particulars

Current P/E Ratio using Basic EPS

(Continuing core operations)**

Current P/E ratio using Diluted EPS***

(Continuing core operation)

Financial Performance as per Audited Financial Statements as per IFRS/IAS or BFRS/BAS

Year

2014

2015-16*

2017
Financial Performance... (Continued)

Year

2014

2015-16*

2017

Details of Financial Statement

Price Sensitive Information

Other Information of the Company

Listing Year

Market Category

Electronic Share

Share Holding Percentage [as on Jun 30, 2017 (year ended)]

Share Holding Percentage [as on Jun 30, 2018]

Share Holding Percentage [as on Jul 31, 2018]

Remarks

Corporate Performance at a glance

Present Operational Status

Present Loan Status as on June 30, 2017

Latest Dividend Status (%)

Latest Credit Rating Status

OTC/Delisting/Relisting

Address of the Company

Address

Contact Phone
Fax

E-mail

Web Address
Scrip Code: 18467

310

4:00 PM

-0.7

-0.23%

307

310.7

310.7

310.2

306.10 - 313.00

5.951

160.70 - 352.90

19,249

231

2,834.09

150

91.22

10

9,121,613

14 May, 2014

Equity

Pharmaceuticals & Chemicals

Total Trade Graph: Total Volume Graph:

For the year ended: Jun 30, 2017

10% 2017,10% 2016

5% 2017, 10% 2016, 25% 2014, 30% 2013, 20% 2012

30-Jun

550.9

0
Unaudited / Audited

Q1 Q2 Half Yearly Q3 9 Months Annual

Ending on Ending on 6 Months Ending on 201803 Ending on

201709 201712 201712 201803

100.2 84.43 184.62 102.88 287.5 -

10.67 5.84 15.58 10.24 27.18 -

10.67 5.84 15.58 10.24 27.18 -

10.67 5.84 15.58 10.24 27.18 -

1.23 0.64 1.71 1.12 2.98 -

- - - - - -

1.23 0.64 1.71 1.12 2.98 -

- - - - - -

164.8 264.4 264.4 343.6 343.6 -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

74.75 76.86 77.16 79.51 78.2 78.07

- - - - - -

12-Aug-18 13-Aug-18 14-Aug-18 16-Aug-18 19-Aug-18 20-Aug-18

71.91 73.95 74.24 76.49 75.23 75.11

75.57 77.71 78.02 80.38 79.06 78.93

Earnings per share(EPS) EPS - Continuing Operations


NAV Per Share
Basic Basic
Diluted Diluted
Original Restated Original Restated Original

- - - 5.79 - - 97.32

Jan'15-Dec'15 - - - 4.01 - - 81.86

Jan'16-Jun'16 - - - 2.07 - - -

Jan'15-Jun'16 - - - 6.07 5.52 - 83.59

- - - 4.13 - - 77.65
Year end Price Earnings (P/E) ratio

Earnings per share(EPS) EPS - Continuing Operations


Dividend in %*
Using Basic EPS Using Using Basic EPS Using

Original Restated Diluted EPS Original Restated Diluted EPS

- - - 45.87 - - 5.00, 25%B

Jan'15-Dec'15 - - - 42.68 - - -

Jan'16-Jun'16 - - - 63.73 - - -

Jan'15-Jun'16 - - - 21.71 46.98 - 10.00, 10%B

- - - 39.16 - - 10.00, 5%B

1992

Sponsor/Director: Govt: Institute: Foreign: Public:

39.42 0 33.09 0 27.49

Sponsor/Director: Govt: Institute: Foreign: Public:

36.41 0 37.5 0 26.09

Sponsor/Director: Govt: Institute: Foreign: Public:

36.41 0 37.5 0 26.09

TK 433,025,425 Revaluation Reserve has been added to Reserve & Surplus.

Active

Short-term loan (mn) 3.03

Long-term loan (mn) 0

10.00, 5%B for 2017

Short-term

Long-term

17/B (3rd Floor), Monipuripara, Sangshad Avenue, Dhaka-1215

58152001, 8155206
-58154213

watachemicals@gmail.com

http://www.watachemical.com
Profit/(Loss) and OCI
NAV Per Share

PCO* Profit for the year (mn) TCI*


Restated Diluted

77.85 - 36.57 - -

- - 31.64 31.64 31.64

- - 16.33 16.33 16.33

76 - 47.97 47.97 47.97

- - 35.85 35.85 35.85


Dividend Yield in %

0.24

0.76

0.62

Vous aimerez peut-être aussi